



REC'D 04 NOV 2004	
WIPO	PCT



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.


In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 10 September 2004

Andrea Govey



The
Patent
Office

1/77

090CT03 E843177-2 002029
P01/7700 0.00-0323585.0

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

KR/JW/PB60531P

2. Patent application number

(The Patent Office will fill in this part)

0323585.0

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)Glaxo Group Limited
Glaxo Wellcome House, Berkeley Avenue,
Greenford, Middlesex UB6 0NN, Great BritainPatents ADP number (*if you know it*)473587003
United Kingdom

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

Compounds

5. Name of your agent (*if you have one*)

Corporate Intellectual Property

"Address for service" in the United Kingdom
to which all correspondence should be sent
(*including the postcode*)GlaxoSmithKline
Corporate Intellectual Property (CN9 25.1)
980 Great West Road
BRENTFORD
Middlesex TW8 9GSPatents ADP number (*if you know it*)

8072555006

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (*if you know it*) the or each application numberCountry Priority application number Date of filing
(*if you know it*) (day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application Date of filing
(*day / month / year*)8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (*Answer yes if:*

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is named as an applicant, or
- c) any named applicant is a corporate body

See note (d)

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form	53
Description	2
Claim(s)	
Abstract	
Drawings	

8

10. If you are also filing any of the following, state how many against each item.

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents
(please specify)

11.

We request the grant of a patent on the basis of this

application

Signature

K Rutter

Date 8-Oct-03

12. Name and daytime telephone number of person to contact in the United Kingdom

K Rutter 01279 644396

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- For details of the fee and ways to pay please contact the Patent Office.

COMPOUNDS

This invention relates to heterocycll compounds, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine, in particular 5 their use in the treatment of conditions mediated by the action of PGE₂ at EP₁ receptors..

The EP₁ receptor is a 7-transmembrane receptor and its natural ligand is the prostaglandin PGE₂. PGE₂ also has affinity for the other EP receptors (types EP₂, EP₃ and EP₄). The EP₁ receptor is associated with smooth muscle contraction, pain (in particular 10 inflammatory, neuropathic and visceral), inflammation, allergic activities, renal regulation and gastric or enteric mucus secretion. We have now found a novel group of compounds which bind with high affinity to the EP₁ receptor.

A number of review articles describe the characterization and therapeutic relevance of the 15 prostanoid receptors as well as the most commonly used selective agonists and antagonists: *Eicosanoids; From Biotechnology to Therapeutic Applications*, Folco, Samuelsson, Maclouf, and Velo eds, Plenum Press, New York, 1996, chap. 14, 137-154 and *Journal of Lipid Mediators and Cell Signalling*, 1996, 14, 83-87 and *Prostanoid Receptors, Structure, Properties and Function*, S Narumiya et al, *Physiological Reviews* 1999, 79(4), 1193-126. An

20 article from *The British Journal of Pharmacology*, 1994, 112, 735- 740 suggests that Prostaglandin E₂ (PGE₂) exerts allodynia through the EP₁ receptor subtype and hyperalgesia through EP₂ and EP₃ receptors in the mouse spinal cord. Furthermore an article from *The Journal of Clinical Investigation*, 2001, 107 (3), 325 shows that in the EP₁ knock-out mouse pain-sensitivity responses are reduced by approximately 50%. Two papers from *Anesthesia and Analgesia* have shown that (2001, 93, 1012-7) an EP₁ receptor antagonist (ONO-8711) 25 reduces hyperalgesia and allodynia in a rat model of chronic constriction injury, and that (2001, 92, 233-238) the same antagonist inhibits mechanical hyperalgesia in a rodent model of post-operative pain. S. Sarkar et al in *Gastroenterology*, 2003, 124(1), 18-25 demonstrate the efficacy of EP₁ receptor antagonists in the treatment of visceral pain in a human model of

30 hypersensitivity. Thus, selective prostaglandin ligands, agonists or antagonists, depending on which prostaglandin E receptor subtype is being considered, have anti-inflammatory, antipyretic and analgesic properties similar to a conventional non-steroidal anti-inflammatory drug, and in addition, inhibit hormone-induced uterine contractions and have anti-cancer effects. These compounds have a diminished ability to induce some of the mechanism-based


35 side effects of NSAIDs which are indiscriminate cyclooxygenase inhibitors. In particular, the compounds have a reduced potential for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced effect on bleeding times and a lessened ability to induce asthma attacks in aspirin-sensitive asthmatic subjects. Moreover, by sparing potentially beneficial prostaglandin pathways, these agents may have enhanced efficacy over NSAIDS and/or

40 COX-2 inhibitors.

In The American Physiological Society (1994, 267, R289-R-294), studies suggest that PGE₂-induced hyperthermia in the rat is mediated predominantly through the EP₁ receptor. WO 96/06822 (March 7, 1996), WO 96/11902 (April 25, 1996), EP 752421-A1 (January 08, 1997) and WO 01/19814 (22 March 2001) disclose compounds as being useful in the treatment of prostaglandin mediated diseases.

It is now suggested that a novel group of heterocyclyl derivatives surprisingly are selective for the EP₁ receptor over the EP₃ receptor, and are therefore indicated to be useful in treating conditions mediated by the action of PGE₂ at EP₁ receptors. Such conditions include pain, or inflammatory, immunological, bone, neurodegenerative or renal disorders.

Accordingly the present invention provides compounds of formula (I):



(I)

wherein:

15 A represents an optionally substituted aryl, or an optionally substituted 5- or 6- membered heterocyclyl ring, or an optionally substituted bicyclic heterocyclyl group;

B represents a phenyl or pyridyl ring;

D represents an optionally substituted 5- or 6-membered heterocyclyl ring containing one or two heteroatoms selected from N, S and O;

20 Z represents O, S, SO, or SO₂;

R¹ represents CO₂H, CN, CONR⁵R⁶, CH₂CO₂H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted SO₂alkyl, SO₂NR⁵R⁶, NR⁵CONR⁵R⁶, COalkyl, 2H-tetrazol-5-yl-methyl, optionally substituted bicyclic heterocycle or optionally substituted heterocyclyl;

25 R^{2a} and R^{2b} independently represents hydrogen, halo, optionally substituted alkyl, optionally substituted alkoxy, CN, SO₂alkyl, SR⁵, NO₂, optionally substituted aryl, CONR⁵R⁶ or optionally substituted heteroaryl;

R^x represents optionally substituted alkyl wherein 1 or 2 of the non-terminal carbon atoms are optionally replaced by a group independently selected from NR⁴, O and SO_n, wherein n is 0, 1 or 2; or R^x represents optionally substituted alkenyl, optionally substituted CQ^aQ^b-heterocyclyl, optionally substituted CQ^aQ^b-bicyclic heterocyclyl or optionally substituted CQ^aQ^b-aryl;

R⁴ represents hydrogen or an optionally substituted alkyl;

R⁵ represents hydrogen or an optionally substituted alkyl;

R^6 represents hydrogen or optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted SO_2 aryl, optionally substituted SO_2 alkyl, optionally substituted SO_2 heteroaryl, CN, optionally substituted CQ^aQ^b aryl, optionally substituted CQ^aQ^b heteroaryl or COR^7 ;


5 R^7 represents hydrogen, optionally substituted alkyl, optionally substituted heteroaryl or optionally substituted aryl;

Q^a and Q^b are independently selected from hydrogen and CH_3 ;

wherein when A is a 6-membered ring the R^1 substituent and the D ring are attached to carbon atoms 1,2-, 1,3- or 1,4- relative to each other, and when A is a five-membered ring

10 or bicyclic heterocyclyl group the R^1 substituent and the D ring are attached to substitutable carbon atoms 1,2- or 1,3- relative to each other;
and derivatives thereof;

provided that D is not imidazolyl, thienyl,



wherein A and B are as hereinbefore defined.

15


In one aspect the A and B rings are attached to adjacent carbon atoms of the central D ring.

20 An example of A includes optionally substituted phenyl.

25 Optional substituents for A include up to four substituents, preferably 0 or 1 substituent, independently selected from halogen, NR^5R^6 , NR^5COC_{1-6} alkyl, $NR^5SO_2C_{1-6}$ alkyl, OR^5 , optionally substituted C_{1-6} alkyl e.g. CH_3 and CF_3 , and $NR^{10}R^{11}$ wherein R^{10} and R^{11} together with the nitrogen atom to which they are attached form a morpholine ring, a 5- or 6-membered lactam ring or a 5- or 6-membered cyclic sulphonamide, wherein R^5 and R^6 are as defined above. Particular optional substituents for A are selected from halogen, NH_2 , NHC_{1-4} alkyl, $NHCOC_{1-4}$ alkyl, and optionally substituted C_{1-4} alkyl e.g. CH_3 and CF_3 .

30 When B is pyridyl, preferably the pyridine N atom is situated adjacent to the ring carbon carrying either the cyclopentene or Z substituent.


Suitably D includes:



all of which may be optionally substituted.

5 Optional substituents for D include C_{1-4} alkyl, oxo, halogen, and CF_3 . D may be substituted by up to four optional substituents, for example one or two substituents.

Preferably D includes:



10 Suitably R^1 includes CO_2H , $CONR^5R^6$ e.g. $CONHSO_2$ phenyl, CH_2CO_2H , SO_2C_{1-6} alkyl, $SO_2NR^5R^6$, $NR^5CONR^5R^6$, or tetrazolyl. Preferably R^1 represents CO_2H .

Preferably Z is O.

15 Suitably R^{2a} and R^{2b} are selected from hydrogen, halo, optionally substituted C_{1-6} alkyl, e.g. CH_3 and CF_3 , and optionally substituted C_{1-6} alkoxy.

Preferably R^{2a} is hydrogen.

20 Preferably R^{2b} represents hydrogen, halo, CF_3 , C_{1-4} alkyl, or C_{1-4} alkoxy, more preferably R^{2b} represents hydrogen, halo, or CF_3 .

Preferably R^{2b} is positioned 1,4- relative to the Z substituent and 1,3- relative to the D ring.

25 Preferably R^4 is hydrogen or C_{1-4} alkyl.

Suitably R⁵ includes hydrogen or C₁₋₄alkyl.

Suitably R⁶ includes hydrogen, C₁₋₄alkyl, or SO₂phenyl.

5 Suitably R⁷ includes hydrogen or C₁₋₄alkyl.

Suitably R^x when an optionally substituted alkyl group includes C₁₋₈alkyl.

Suitably R^x includes C₁₋₈alkyl, CH₂phenyl optionally substituted by one, two or three

10 substituents selected from Cl, Br, F, CF₃, C₁₋₄alkyl, and OC₁₋₄alkyl.

A suitable example of Q_a is hydrogen.

A suitable example of Q_b is hydrogen.

15

Compounds of formula (I) include:

3-[1-[2-(Benzyl)-phenyl]-5-methyl-1H-pyrrol-2-yl]-benzoic acid;

3-[1-[2-(Benzyl)-5-chloro-phenyl]-5-methyl-1H-pyrrol-2-yl]-benzoic acid;

3-[1-[2-(Benzyl)-5-bromo-phenyl]-5-methyl-1H-pyrrol-2-yl]-benzoic acid;

20 3-[5-[2-(Benzyl)-phenyl]-1H-pyrazol-1-yl]-benzoic acid;

3-[5-[2-(Benzyl)-5-chloro-phenyl]-1H-pyrazol-1-yl]-benzoic acid;

3-[3-[2-(Benzyl)-5-chloro-phenyl]-pyrazin-2-yl]-benzoic acid;

3-[4-[2-(Benzyl)-5-chloro-phenyl]-2-oxo-2,5-dihydro-furan-3-yl]-benzoic acid;

3-[3-[2-(Benzyl)-5-chloro-phenyl]-2-oxo-2,5-dihydro-furan-4-yl]-benzoic acid;

25 3-[3-[2-(Benzyl)-5-chloro-phenyl]-pyridin-4-yl]-benzoic acid;

3-[3-[2-(Benzyl)-phenyl]-pyridin-4-yl]-benzoic acid;

3-[4-[2-(Benzyl)-5-chloro-phenyl]-pyridin-3-yl]-benzoic acid;

3-[3-[2-(Benzyl)-5-chloro-phenyl]-pyridin-2-yl]-benzoic acid;

3-[3-[2-(Benzyl)-5-(trifluoromethyl)-phenyl]-pyridin-4-yl]-5-(acetylamino)-benzoic acid;

30 3-[3-[2-(4-Fluoro-benzyl)-5-(trifluoromethyl)-phenyl]-pyridin-4-yl]-5-(acetylamino)-

benzoic acid;

3-[3-[2-(2,4-Difluoro-benzyl)-5-(trifluoromethyl)-phenyl]-pyridin-4-yl]-5-(acetylamino)-benzoic acid; and

3-[3-[2-(Benzyl)-phenyl]-pyridin-4-yl]-5-(acetylamino)-benzoic acid;

35 and derivatives thereof.

Preferably compounds are selective for EP₁ over EP₃.

Derivatives of the compounds of formula (I) include pharmaceutically acceptable derivatives.

40

The invention is described using the following definitions unless otherwise indicated.

The term "pharmaceutically acceptable derivative" means any pharmaceutically acceptable salt, ester, salt of such ester or solvate of the compounds of formula (I), or any other compound which upon administration to the recipient is capable of providing (directly or indirectly) a compound of formula (I).

5 It will be appreciated by those skilled in the art that the compounds of formula (I) may be modified to provide pharmaceutically acceptable derivatives thereof at any of the functional groups in the compounds, and that the compounds of formula (I) may be derivatised at more than one position.

10 It will be appreciated that, for pharmaceutical use, the salts referred to above will be pharmaceutically acceptable salts, but other salts may find use, for example in the preparation of compounds of formula (I) and the pharmaceutically acceptable salts thereof.

15 Pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse, J. Pharm. Sci., 1977, 66, 1-19. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropyl amine, tromethamine, and the like. When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acid.

30 Preferred examples of pharmaceutically acceptable salts include those formed from maleic, fumaric, benzoic, ascorbic, pamoic, succinic, bismethylenesalicylic, methanesulfonic, ethanesulfonic, propionic, tartaric, salicylic, citric, gluconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, cyclohexylsulfamic, phosphoric and nitric acids.

40

The compounds of formula (I) may be prepared in crystalline or non-crystalline form, and if crystalline, may be optionally hydrated or solvated. This invention includes in its scope stoichiometric hydrates as well as compounds containing variable amounts of water.

5 Suitable solvates include pharmaceutically acceptable solvates, such as hydrates.

Solvates include stoichiometric solvates and non-stoichiometric solvates.

The terms "halogen" or "halo" are used to represent fluorine, chlorine, bromine or iodine.

10 The term "alkyl" as a group or part of a group means a straight, branched or cyclic chain alkyl group or combinations thereof, for example methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, pentyl, hexyl, 1,1-dimethylethyl, cyclopentyl or cyclohexyl or combinations thereof such as cyclohexylmethyl and cyclopentylmethyl. Unless otherwise defined, 15 preferably "alkyl" is C₁₋₆alkyl, more preferably "alkyl" is C₁₋₆alkyl.

20 The term "alkoxy" as a group or as part of a group means a straight, branched or cyclic chain alkyl group having an oxygen atom attached to the chain, for example a methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy group, pentoxy, hexyloxy group, cyclopentoxy or cyclohexyloxy group. Preferably "alkoxy" is C₁₋₆ alkoxy.

25 The term "alkenyl" means linear or branched structures and combinations thereof, of the indicated number of carbon atoms, having at least one carbon-to-carbon double bond, wherein hydrogen may be replaced by an additional carbon to carbon double bond. Preferably "alkenyl" is C₂₋₆alkenyl. C₂₋₆alkenyl, for example, includes ethenyl, propenyl, 1-methylethenyl, butenyl and the like.

30 The term "heterocyclyl" as a group or as part of a group unless hereinbefore defined means an aromatic or non-aromatic five or six membered ring which contains from 1 to 4 heteroatoms selected from nitrogen, oxygen or sulfur and unsubstituted or substituted by, for example, up to three substituents. Examples of 5- membered heterocyclyl groups include furyl, dioxalanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, triazinyl, isothiazolyl, isoxazolyl, thiophenyl, pyrazolyl or tetrazolyl. Examples of 6-membered heterocyclyl groups are pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl or 35 tetrazinyl.

40 The term "aryl" as a group or part of a group means a 5- or 6- membered aromatic ring, for example phenyl, or a 7 to 12 membered bicyclic ring system where at least one of the rings is aromatic, for example naphthyl. An aryl group may be optionally substituted by one or more substituents, for example up to 4, 3 or 2 substituents. Preferably the aryl group is phenyl.

The term "heteroaryl" as a group or as part of a group means a monocyclic five or six membered aromatic ring, or a fused bicyclic aromatic ring system comprising two of such monocyclic five or six membered aromatic rings. These heteroaryl rings contain one or more heteroatoms selected from nitrogen, oxygen or sulfur, where N-oxides, sulfur oxides and sulfur dioxides are permissible heteroatom substitutions. A heteroaryl group may be 5 optionally substituted by one or more substituents, for example up to 3 or up to 2 substituents. Examples of "heteroaryl" used herein include furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, benzofuryl, 10 benzothienyl, indolyl, and indazolyl.

The term "bicyclic heterocycl" when used herein means a fused bicyclic aromatic or non-aromatic bicyclic heterocycl ring system comprising up to four, preferably one or two, heteroatoms each selected from oxygen, nitrogen and sulphur. Each ring may have from 15 4 to 7, preferably 5 or 6, ring atoms. A bicyclic heteroaromatic ring system may include a carbocyclic ring. Examples of bicyclic heterocycl groups include quinolinyl, isoquinolinyl, quinoxaliny, quinazolinyl, pyridopyrazinyl, benzoxazolyl, benzothiophenyl, benzimidazolyl, benzothiazolyl, benzoxadiazolyl, benzthiadiazolyl, indolyl, benztriazolyl or naphthyridinyl.

20 When the heteroatom nitrogen replaces a carbon atom in an alkyl group, or when nitrogen is present in a heteroaryl, heterocycl or bicyclic heterocycl group, the nitrogen atom will, where appropriate, be substituted by one or two substituents selected from hydrogen and C₁₋₈alkyl; preferably hydrogen and C₁₋₆alkyl, more preferably hydrogen.


25 Optional substituents for alkyl or alkenyl groups unless hereinbefore defined include OH, CO₂R⁴, NR⁴R⁵, (O), -OC₁₋₆alkyl or halo e.g. Cl, Br or F, wherein R⁴, and R⁵ are as hereinbefore defined for compounds of formula (I). An alkyl or alkenyl group may be substituted by one or more optional substituents, for example up to 5, 4, 3, or 2 optional substituents. Particular substituted alkyl groups include those substituted by one or more fluorines e.g. CH₂F, CHF₂, 30 CF₃, C₂F₅, etc, especially CF₃.

Optional substituents for alkoxy groups unless hereinbefore defined include OH, and halo e.g. Cl, Br or F. An alkoxy group may be substituted by one or more optional substituents, for example up to 5, 4, 3, or 2 optional substituents. Particular substituted alkoxy groups include those substituted by one or more fluorines e.g. OCH₂F, OCHF₂, OCF₃, OC₂F₅ etc.

35 Unless otherwise defined, optional substituents for aryl, heteroaryl or heterocycl moieties as a group or part of a group are selected from optionally substituted C₁₋₆alkyl, optionally substituted C₁₋₆alkoxy and halogen.

40 Compounds of formula (I) can be prepared as set forth in the following schemes and in the examples. The following processes form another aspect of the present invention.

For example, compounds of formula (Ia) which are compounds of formula (I) wherein the A and B rings are attached to adjacent carbon atoms of the central D ring, e.g. pyridinyl, dihydrofuranyl etc, may be prepared by the general route below:



5 wherein L¹, L², are leaving groups for example halo, or triflate; L³ and L⁴ are activating groups, for example boronic acid; P is an optional protecting group; D is an optionally substituted 5- or 6-membered heterocyclic ring containing one or two heteroatoms selected from N, S and O wherein A and B are attached through ring carbon atoms; and 10 A, B, R¹, R^{2a}, R^{2b}, Z and R^x are as defined for compounds of formula (I). L¹ can be converted to L^{1a}, and L² can be converted to L^{2a} wherein L^{1a} and L^{2a} are activating groups for example a boronic acid, and in this situation L³ and L⁴ can be halo or triflate.


15 When R¹ is CO₂H examples of P include methyl, ethyl or optionally substituted benzyl esters.

Suitable reaction conditions for the deprotection of a compound of formula (II) include heating in aqueous ethanolic sodium hydroxide solution.

20 Suitable reaction conditions for the reaction of a compound of formula (VI) with a boronic acid of formula (V, L³ is —B(OH)₂), or a compound of formula (IV) with a boronic acid of formula (III, L⁴ is —B(OH)₂) include heating with tetrakis(triphenylphosphine)palladium (0)

and an inorganic base, for example potassium carbonate, in a solvent, e.g. ethylene glycol dimethyl ether (DME), toluene and ethanol, preferably in a ratio of 1:1.

5 Accordingly the present invention also provides a process for the preparation of a compound of formula (Ia) or a derivative thereof:



(I)

wherein:

A represents an optionally substituted aryl, or an optionally substituted 5- or 6- membered 10 heterocycl ring, or an optionally substituted bicyclic heterocycl group;

B represents a phenyl or pyridyl ring;

D represents an optionally substituted 5- or 6-membered heterocycl ring containing one or two heteroatoms selected from N, S and O wherein the A and B rings are attached to adjacent carbon atoms of the central D ring;

15 Z represents O, S, SO, or SO₂;

R¹ represents CO₂H, CN, CONR⁵R⁶, CH₂CO₂H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted SO₂alkyl, SO₂NR⁵R⁶, NR⁵CONR⁵R⁶, COalkyl, 2H-tetrazol-5-yl-methyl, optionally substituted bicyclic heterocycle or optionally substituted heterocycl;

20 R^{2a} and R^{2b} independently represents hydrogen, halo, optionally substituted alkyl, optionally substituted alkoxy, CN, SO₂alkyl, SR⁵, NO₂, optionally substituted aryl, CONR⁵R⁶ or optionally substituted heteroaryl;

R^x represents optionally substituted alkyl wherein 1 or 2 of the non-terminal carbon atoms 25 may optionally be replaced by a group independently selected from NR⁴, O and SO_n, wherein n is 0, 1 or 2; or R^x represents optionally substituted alkenyl, optionally substituted CQ^aQ^b-heterocycl, optionally substituted CQ^aQ^b-bicyclic heterocycl or optionally substituted CQ^aQ^b-aryl;

R⁴ represents hydrogen or an optionally substituted alkyl;

R⁵ represents hydrogen or an optionally substituted alkyl;

30 R⁶ represents hydrogen or optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted SO₂aryl, optionally substituted SO₂alkyl, optionally substituted SO₂heteroaryl, CN, optionally substituted CQ^aQ^baryl, optionally substituted CQ^aQ^bheteroaryl or COR⁷;

R^7 represents hydrogen, optionally substituted alkyl, optionally substituted heteroaryl or optionally substituted aryl;


Q^a and Q^b are independently selected from hydrogen and CH_3 ;

wherein when A is a 6-membered ring the R^1 substituent and the D ring are attached to

5 carbon atoms 1,2-, 1,3- or 1,4- relative to each other, and when A is a five-membered ring or bicyclic heterocyclyl group the R^1 substituent and the D ring are attached to substitutable carbon atoms 1,2- or 1,3- relative to each other;

comprising:


reacting a compound of formula (IV):



(IV)

10

wherein A, D and R^1 are as hereinbefore defined above for a compound of formula (Ia), L^1 is a leaving group and P is an optional protecting group; with a compound of formula (III):



(III)

15 wherein R^{2a} , R^{2b} , B, Z, and R^x are as hereinbefore defined above for a compound of formula (I) and L^4 is an activating group;

and where required converting:

one group A to another group A, and/or

20 one group R^x to another group R^x ;

and where required carrying out the following optional steps in any order:


effecting deprotection; and/or

converting one group R^1 to another group R^1 ; and/or

forming a derivative of the compound of formula (Ia) so formed.


25

Alternatively compounds of formula (Ia) may be prepared according to the route described below:



5 wherein L^1 , L^2 , L^3 , L^4 and P are as defined above, and A , B , R^1 , R^{2a} , R^{2b} , Z , and R^x are as defined for compounds of formula (I). L^1 can be converted to L^{1a} , and L^2 can be converted to L^{2a} wherein L^{1a} and L^{2a} are activating groups for example a boronic acid, and in this situation L^3 and L^4 can be halo or triflate.

Accordingly the present invention also provides a process for the preparation of a compound of formula (Ia) or a derivative thereof:



(Ia)

wherein:

A represents an optionally substituted aryl, or an optionally substituted 5- or 6- membered heterocycl ring, or an optionally substituted bicyclic heterocycl group;

5 B represents a phenyl or pyridyl ring;

D represents an optionally substituted 5- or 6-membered heterocycl ring containing one or two heteroatoms selected from N, S and O wherein the A and B rings are attached to adjacent carbon atoms of the central D ring;

Z represents O, S, SO, or SO₂;

10 R¹ represents CO₂H, CN, CONR⁵R⁶, CH₂CO₂H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted SO₂alkyl, SO₂NR⁵R⁶, NR⁵CONR⁵R⁶, COalkyl, 2H-tetrazol-5-yl-methyl, optionally substituted bicyclic heterocycle or optionally substituted heterocycl;

R^{2a} and R^{2b} independently represents hydrogen, halo, optionally substituted alkyl,

15 optionally substituted alkoxy, CN, SO₂alkyl, SR⁵, NO₂, optionally substituted aryl, CONR⁵R⁶ or optionally substituted heteroaryl;

R^x represents optionally substituted alkyl wherein 1 or 2 of the non-terminal carbon atoms may optionally be replaced by a group independently selected from NR⁴, O and SO_n, wherein n is 0, 1 or 2; or R^x represents optionally substituted alkenyl, optionally substituted

20 CQ^aQ^b-heterocycl, optionally substituted CQ^aQ^b-bicyclic heterocycl or optionally substituted CQ^aQ^b-aryl;

R⁴ represents hydrogen or an optionally substituted alkyl;

R⁵ represents hydrogen or an optionally substituted alkyl;

R⁶ represents hydrogen or optionally substituted alkyl, optionally substituted heteroaryl,

25 optionally substituted SO₂aryl, optionally substituted SO₂alkyl, optionally substituted SO₂heteroaryl, CN, optionally substituted CQ^aQ^baryl, optionally substituted CQ^aQ^bheteroaryl or COR⁷;


R⁷ represents hydrogen, optionally substituted alkyl, optionally substituted heteroaryl or optionally substituted aryl;

30 Q^a and Q^b is independently selected from hydrogen and CH₃;


wherein when A is a 6-membered ring the R¹ substituent and the D ring are attached to carbon atoms 1,2-, 1,3- or 1,4- relative to each other, and when A is a five-membered ring or bicyclic heterocycl group the R¹ substituent and the D ring are attached to substitutable carbon atoms 1,2- or 1,3- relative to each other;

comprising:

reacting a compound of formula (VII):



wherein R^{2a}, R^{2b}, B, D, R^x and R¹ are as hereinbefore defined above for a compound of
 5 formula (Ia), and L² is a leaving group;
 with a compound of formula (V):




(V)

wherein R¹, and A are as hereinbefore defined above for a compound of formula (I); L³ is
 an activating group and P is an optional protecting group;

10 and where required converting:
 one group A to another group A, and/or
 one group R^x to another group R^x;
 and where required carrying out the following optional steps in any order:
 effecting deprotection; and/or
 15 converting one group R¹ to another group R¹; and/or
 forming a derivative of the compound of formula (Ia) so formed.

Compounds of formula (Ib) which are compounds of formula (I) wherein the central D ring is
 20 1H-pyrazolyl substituted by A on the 1-position and B on the 5-position may be prepared by
 the general route below:



wherein A, B, R¹, R^{2a}, R^{2b}, Z, and R^x are as hereinbefore defined for compounds of formula (I), R is an ester forming group such as C₁₋₄alkyl and P is an optional protecting group.

5

When R¹ is CO₂H, a suitable protecting group P is an ester forming group such as C₁₋₄alkyl or optionally substituted benzyl. Suitable reaction conditions for the deprotection of a compound of formula (II) include hydrolysis effected by e.g. heating in ethanolic sodium hydroxide solution, or hydrogenation.


10

Suitable conditions for the conversion of a compound of formula (VIII) to a compound of formula (Ib) include heating under nitrogen at 190-220°C.

Suitable reaction conditions for the reaction of a hydrazine (X) or a salt thereof with a compound of formula (XI) include heating at reflux in a solvent such as a C₁₋₄alcohol, e.g. methanol.

5 Suitable reaction conditions for the preparation of a compound of formula (XI) include reacting a methyl ketone of formula (XII) with a dialkyl oxalate, e.g. dimethyl oxalate, in a C₁₋₄alcohol e.g. methanol, in the presence of a sodium alkoxide, e.g sodium methoxide.

Accordingly the present invention also provides a process for the preparation of a compound of formula (Ib) or a derivative thereof:




wherein:

A, B, Z, R¹, R^{2a}, R^{2b}, and R^x are as defined for compounds of formula (I)


comprising:

15 reacting a compound of formula (XI):




wherein R^{2a}, R^{2b}, B, R^x, and Z are as hereinbefore defined above for a compound of formula (Ib), and R is an ester forming group;

with a compound of formula (X):



(X)

20 or a salt thereof, wherein R¹ and A are as hereinbefore defined above for a compound of formula (Ib); and P is an optional protecting group; to give a compound of formula (IX):




wherein R^{2a}, R^{2b}, A, B, Z, R^x, R¹, R and P are as hereinbefore defined and, if necessary, effecting deprotection; and effecting decarboxylation;

5 and if necessary converting one group R¹ to another group R¹; and/or forming a derivative of the compound of formula (Ib) so formed.

Compounds of formula (Ic) which are compounds of formula (I) wherein the central D ring is 1H-pyrrolyl substituted by A on the 2-position and B on the 1-position may be prepared by

10 the general route below:




wherein A, B, R¹, R^{2a}, R^{2b}, Z and R^x are as defined for compounds of formula (I), R⁸ and R⁹ independently selected from hydrogen, CF₃ or C₁₋₄alkyl, and P is an optional protecting group.

5 When R¹ is CO₂H, a suitable protecting group P is an ester forming group such as C₁₋₄alkyl or optionally substituted benzyl. Suitable reaction conditions for the deprotection of a compound of formula (II) include hydrolysis effected by e.g. heating in ethanolic sodium hydroxide solution, or hydrogenation.

10 Suitable reaction conditions for the reaction of a compound of formula (XIV) with a compound of formula (XV) to give a pyrrole of formula (XIII) include heating with an acid catalyst e.g. p-toluenesulfonic acid in a solvent such as toluene. Reviews of pyrrole synthesis can be found in e.g. A. Triebs, *Chem. Ber.*, 1957, 90, 79-84, E. Baltazzi *et al*, *Chem. Rev.*, 1963, 63, 511, and R.A. Jones, *Advances in Heterocyclic Chemistry*, 1970, 11, 383.

15 Suitable reaction conditions for the preparation of a compound of formula (XV) include reacting a compound of formula (XVI) with a suitable vinyl ketone e.g. methyl vinyl ketone in the presence of 3-ethyl-5-(2-hydroxyethyl)-4-methylthiazolium bromide and a base such as triethylamine in a solvent e.g. a C₁₋₄alcohol e.g. ethanol at reflux.

Accordingly the present invention also provides a process for the preparation of a compound of formula (Ic) or a derivative thereof:




25 wherein:

wherein A, B, R¹, R^{2a}, R^{2b}, Z and R^x are as defined for compounds of formula (I), and R⁸ and R⁹ are independently selected from hydrogen, CF₃ or C₁₋₄alkyl;


comprising:

reacting a compound of formula (XV):



30 wherein A, R⁸, R⁹, and R¹ are as hereinbefore defined above for a compound of formula (Ic), and P is an optional protecting group;

with a compound of formula (XIV):



wherein R^{2a} , R^{2b} , B, Z, and R^x are hereinbefore defined above for a compound of formula (Ic); and P is an optional protecting group;

5 and where required converting:

one group A to another group A, and/or
one group R^x to another group R^x ;

and where required carrying out the following optional steps in any order:
effecting deprotection; and/or

10 converting one group R^1 to another group R^1 ; and/or

forming a derivative of the compound of formula (Ic) so formed.

A group R^1 may be converted to another group R^1 by use of conventional organic transformations known to those skilled in the art. For example $R^1 = CO_2H$ may be converted to an amide, e.g. $CONHCQ^aQ^b$ aryl or $CONHCQ^aQ^b$ heteroaryl wherein Q^a and Q^b are hydrogen or CH_3 , by conventional methods for the preparation of amides as described in, for example, Richard Larock, *Comprehensive Organic Transformations*, 2nd edition, Wiley-VCH, ISBN 0-471-19031-4.

20 The preparation and reactions of boronic acids of formula (III) and formula (V) is reviewed in Suzuki *et al*, *Synth. Commun.*, 1981, 11, 513; Martin *et al*, *Acta. Chim. Scand.*, 1993, 47, 221; and Miyaura *et al*, *Chem. Rev.*, 1995, 95, 2457. For example, 2-benzyloxy-5-chlorophenylboronic acid may be prepared from 2-benzyloxy-5-chloro-iodobenzene. 2-Benzyl-5-chloro-iodobenzene may be prepared from 4-chloro-2-iodoanisole by demethylation followed by benzylation according to known methods.

25 Certain substituents in any of the reaction intermediates and compounds of formula (I) may be converted to other substituents by conventional methods known to those skilled in the art. Examples of substituents which may be converted include one group R^x to another group R^x ; and one substituent on a group A to another substituent on a group A. Examples of such transformations include the reduction of a nitro group to give an amino group; alkylation and amidation of amino groups; hydrolysis of esters, alkylation of hydroxy and amino groups; and amidation and esterification of carboxylic acids. Such transformations are well known to those skilled in the art and are described in for example, Richard Larock, *Comprehensive Organic Transformations*, 2nd edition, Wiley-VCH, ISBN 0-471-19031-4.

For example, when R^x is p-methoxybenzyl, cleavage of the ether to give the phenol or pyridinol is carried out using, for example, using acid e.g. HCl/dioxane or HBr/acetic acid, or using sodium methanethiolate. When R^x is methyl, cleavage of the ether to give the phenol is carried out using, for example, sodium methanethiolate. Cleavage of the ether to

5 give a pyridinol is carried out in the presence of, for example, trifluoroacetic acid.

Conversion to another R^x group, for example a substituted benzyl group, may be effected by reaction of the phenol or pyridinol with a suitable substituted benzyl bromide. The skilled person will appreciate that conversion of the protecting group P to another protecting group P may also occur under the reaction conditions used. When R^x is benzyl,


10 cleavage of the ether to give the phenol or pyridinol may be carried out by hydrogenation according to known methods e.g. H_2 -Pd/C or NH_4CO_2H -Pd/C. The resulting phenol or pyridinol can then be converted to another group R^x as described above.

It will be appreciated by those skilled in the art that it may be necessary to protect certain reactive substituents during some of the above procedures. The skilled person will

15 recognise when a protecting group is required. Standard protection and deprotection techniques, such as those described in Greene T.W. 'Protective groups in organic synthesis', New York, Wiley (1981), can be used. For example, carboxylic acid groups can be protected as esters. Deprotection of such groups is achieved using conventional


20 procedures known in the art. It will be appreciated that protecting groups may be interconverted by conventional means.

Compounds of the formula (III):



25 wherein L^4 is as hereinbefore defined, R^{2a} , R^{2b} , Z, B and R^x and are as defined for compounds of formula (I) are commercially available, or may readily be prepared by methods known to those skilled in the art, for example from suitable commercially available pyridinols, anisoles or phenols using methods as described in the examples.

30 Intermediates of the formula (VI):



wherein L^1 , L^2 are as defined above, and D is as hereinbefore defined for compounds of formula (Ia) are commercially available or may be readily prepared according to known methods for the preparation of heterocycles. The preparation of

heterocycles is reviewed in e.g. *Comprehensive heterocyclic chemistry. The structure, reactions, synthesis and uses of heterocyclic compounds*, A.R. Katritzky and C.W. Rees (Eds), vols 1-8, Pergamon Press, Oxford, 1984; *Comprehensive organic chemistry II. A review of the literature 1982-1995*, A.R. Katritzky, C.W. Rees, and E.F.V. Scriven (eds),

5 vols 1-11, Pergamon Press, Oxford, 1996, and *Heterocyclic Chemistry*, 4th Edition, J.A. Joule and K. Mills, Blackwell Science, 2000.

Compounds of the formula (V):



10 wherein L^3 and P are as defined above and R^1 and A are as hereinbefore defined for compounds of formula (I) are commercially available or may readily be prepared, for example, from suitable halobenzoic acid esters according to known methods, for example using methods as described in the examples.


15 Hydrazines of formula (X) are commercially available, or may be readily prepared by methods known to those skilled in the art for the preparation of hydrazines.

Intermediates of formula (XII) are commercially available, or may readily be prepared by standard transformations known to those skilled in the art, for example from suitable 20 commercially available starting materials using methods as described in the examples. The preparation of ketones is reviewed in *The Chemistry of the Carbonyl Group*, S. Patai (Ed), Interscience, New York, 1966, and references cited therein.

25 Amines of formula (XIV) are commercially available, or may be prepared from commercial materials by standard transformations known to those skilled in the art, for example using methods as described in the examples, e.g. from ortho-nitrophenols by reaction with R^XBr , followed by reduction of the nitro group to an amine group.

30 Aldehydes of formula (XVI) are commercially available, or may be made by standard methods as described, for example, in *The Chemistry of the Carbonyl Group*, S. Patai (Ed), Interscience, New York, 1966, and references cited therein.

Vinyl ketones of formula:



35 wherein R^8 and R^9 are as hereinbefore defined for compounds of formula (Ic) are commercially available or may be readily prepared according to known methods for the preparation of vinyl ketones. For example, $F_3CCOCHCH_2=CH_2$ may be prepared according to the method of M. Tordeux *et al*, *J. Fluorine Chemistry*, 1982, 20(3), 301-306.

It is to be understood that the present invention encompasses all isomers of formula (I) and their pharmaceutically acceptable derivatives, including all geometric, tautomeric and optical forms, and mixtures thereof (e.g. racemic mixtures). Where additional chiral centres are present in compounds of formula (I), the present invention includes within its scope all possible diastereoisomers, including mixtures thereof. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.

5 10 The compounds of the invention bind to the EP₁ receptor and are therefore useful in treating conditions mediated by the action of PGE₂ at EP₁ receptors.

In view of their ability to bind to the EP₁ receptor, the compounds of the invention may be useful in the treatment of the disorders that follow.

15 The compounds of formula (I) may be useful as analgesics. They are therefore useful in the treatment or prevention of pain.

20 The compounds of formula (I) may be used as an analgesic to treat acute pain, chronic pain, neuropathic pain, inflammatory pain, visceral pain, pain associated with cancer and fibromyalgia, pain associated with migraine, tension headache and cluster headaches, and pain associated with functional bowel disorders, non-cardiac chest pain and non-ulcer dyspepsia.

25 The compounds of formula (I) may be useful in the treatment of chronic articular pain (e.g. rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis) including the property of disease modification and joint structure preservation; musculoskeletal pain; lower back and neck pain; sprains and strains; neuropathic pain; sympathetically maintained pain; myositis; pain associated with cancer and fibromyalgia; 30 pain associated with migraine; pain associated with influenza or other viral infections, such as the common cold; rheumatic fever; pain associated with functional bowel disorders such as non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome; pain associated with myocardial ischemia; post operative pain; headache; toothache; and dysmenorrhea. The compounds of the invention may also be useful in the treatment of 35 visceral pain.

40 The compounds of the invention may be particularly useful in the treatment of neuropathic pain. Neuropathic pain syndromes can develop following neuronal injury and the resulting pain may persist for months or years, even after the original injury has healed. Neuronal injury may occur in the peripheral nerves, dorsal roots, spinal cord or certain regions in the brain. Neuropathic pain syndromes are traditionally classified according to the disease or event that precipitated them. Neuropathic pain syndromes include: diabetic neuropathy;

sciatica; non-specific lower back pain; multiple sclerosis pain; fibromyalgia; HIV-related neuropathy; post-herpetic neuralgia; trigeminal neuralgia; and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions. These conditions are difficult to treat and although several drugs are known to have limited efficacy,

5 complete pain control is rarely achieved. The symptoms of neuropathic pain are heterogeneous and are often described as spontaneous shooting and lancinating pain, or ongoing, burning pain. In addition, there is pain associated with normally non-painful sensations such as "pins and needles" (paraesthesia and dysesthesia), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation
10 (dynamic, static or thermal allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia).

The compounds of formula (I) may also be useful in the treatment of fever.

15 The compounds of formula (I) may also be useful in the treatment of inflammation, for example in the treatment of skin conditions (e.g. sunburn, burns, eczema, dermatitis, psoriasis); ophthalmic diseases such as glaucoma, retinitis, retinopathies, uveitis and of acute injury to the eye tissue (e.g. conjunctivitis); lung disorders (e.g. asthma, bronchitis, emphysema, allergic rhinitis, respiratory distress syndrome, pigeon fancier's disease, farmer's lung, chronic obstructive pulmonary disease, (COPD); gastrointestinal tract disorders (e.g. aphthous ulcer, Crohn's disease, atopic gastritis, gastritis varialoforme, ulcerative colitis, coeliac disease, regional ileitis, irritable bowel syndrome, inflammatory bowel disease, gastrointestinal reflux disease); organ transplantation; other conditions with
20 an inflammatory component such as vascular disease, migraine, periarteritis nodosa, thyroiditis, aplastic anaemia, Hodgkin's disease, sclerodema, myasthenia gravis, multiple sclerosis, sarcoidosis, nephrotic syndrome, Bechet's syndrome, polymyositis, gingivitis, myocardial ischemia, pyrexia, systemic lupus erythematosus, tendinitis, bursitis, and Sjogren's syndrome.

25 The compounds of formula (I) are also useful in the treatment of immunological diseases such as autoimmune diseases, immunological deficiency diseases or organ transplantation. The compounds of formula (I) are also effective in increasing the latency of HIV infection.

30 The compounds of formula (I) are also useful in the treatment of diseases of abnormal platelet function (e.g. occlusive vascular diseases).

35 The compounds of formula (I) are also useful for the preparation of a drug with diuretic action.

40 The compounds of formula (I) are also useful in the treatment of impotence or erectile dysfunction.

The compounds of formula (I) are also useful in the treatment of bone disease characterised by abnormal bone metabolism or resorption such as osteoporosis (especially postmenopausal osteoporosis), hyper-calcemia, hyperparathyroidism, Paget's

5 bone diseases, osteolysis, hypercalcemia of malignancy with or without bone metastases, rheumatoid arthritis, periodontitis, osteoarthritis, ostealgia, osteopenia, cancer cachexia, calculosis, lithiasis (especially urolithiasis), solid carcinoma, gout and ankylosing spondylitis, tendinitis and bursitis.

10 The compounds of formula (I) are also useful for attenuating the hemodynamic side effects of non-steroidal anti-inflammatory drugs (NSAID's) and cyclooxygenase-2 (COX-2) inhibitors.

15 The compounds of formula (I) are also useful in the treatment of cardiovascular diseases such as hypertension or myocardial ischemia; functional or organic venous insufficiency; varicose therapy; haemorrhoids; and shock states associated with a marked drop in arterial pressure (e.g. septic shock).

20 The compounds of formula (I) are also useful in the treatment of neurodegenerative diseases and neurodegeneration such as dementia, particularly degenerative dementia (including senile dementia, Alzheimer's disease, Pick's disease, Huntingdon's chorea, Parkinson's disease and Creutzfeldt-Jakob disease, ALS, motor neuron disease); vascular dementia (including multi-infarct dementia); as well as dementia associated with intracranial space occupying lesions; trauma; infections and related conditions (including

25 HIV infection); metabolism; toxins; anoxia and vitamin deficiency; and mild cognitive impairment associated with ageing, particularly Age Associated Memory Impairment. The compounds of formula (I) are also useful in the treatment of neuroprotection and in the treatment of neurodegeneration following stroke, cardiac arrest, pulmonary bypass, traumatic brain injury, spinal cord injury or the like.

30 The compounds of formula (I) are also useful in the treatment of tinnitus.

35 The compounds of formula (I) are also useful in preventing or reducing dependence on, or preventing or reducing tolerance or reverse tolerance to, a dependence - inducing agent. Examples of dependence inducing agents include opioids (e.g. morphine), CNS depressants (e.g. ethanol), psychostimulants (e.g. cocaine) and nicotine.

40 The compounds of formula (I) are also useful in the treatment of complications of Type 1 diabetes (e.g. diabetic microangiopathy, diabetic retinopathy, diabetic nephropathy, macular degeneration, glaucoma), nephrotic syndrome, aplastic anaemia, uveitis, Kawasaki disease and sarcoidosis.

The compounds of formula (I) are also useful in the treatment of kidney dysfunction (nephritis, particularly mesangial proliferative glomerulonephritis, nephritic syndrome), liver dysfunction (hepatitis, cirrhosis), gastrointestinal dysfunction (diarrhoea) and colon cancer.

5 The compounds of formula (I) are also useful in the treatment of overactive bladder and urge incontinence.

It is to be understood that reference to treatment includes both treatment of established symptoms and prophylactic treatment, unless explicitly stated otherwise.

10 According to a further aspect of the invention, we provide a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in human or veterinary medicine.

15 According to another aspect of the invention, we provide a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in the treatment of a condition which is mediated by the action of PGE₂ at EP₁ receptors.

20 According to a further aspect of the invention, we provide a method of treating a human or animal subject suffering from a condition which is mediated by the action of PGE₂ at EP₁ receptors which comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

25 According to a further aspect of the invention we provide a method of treating a human or animal subject suffering from a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder, which method comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

30 According to a yet further aspect of the invention we provide a method of treating a human or animal subject suffering from inflammatory pain, neuropathic pain or visceral pain which method comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

35 According to another aspect of the invention, we provide the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment of a condition which is mediated by the action of PGE₂ at EP₁ receptors.

40 According to another aspect of the invention we provide the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment or prevention of a condition such as a pain, or an inflammatory, immunological, bone, neurodegenerative or renal disorder.

According to another aspect of the invention we provide the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment or prevention of a condition such as inflammatory pain, neuropathic pain or visceral pain.

The compounds of formula (I) and their pharmaceutically acceptable derivatives are conveniently administered in the form of pharmaceutical compositions. Such compositions may conveniently be presented for use in conventional manner in admixture with one or 10 more physiologically acceptable carriers or excipients.

Thus, in another aspect of the invention, we provide a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof adapted for use in human or veterinary medicine.

15 The compounds of formula (I) and their pharmaceutically acceptable derivatives may be formulated for administration in any suitable manner. They may, for example, be formulated for topical administration or administration by inhalation or, more preferably, for oral, transdermal or parenteral administration. The pharmaceutical composition may be in 20 a form such that it can effect controlled release of the compounds of formula (I) and their pharmaceutically acceptable derivatives.

For oral administration, the pharmaceutical composition may take the form of, for example, 25 tablets (including sub-lingual tablets), capsules, powders, solutions, syrups or suspensions prepared by conventional means with acceptable excipients.

For transdermal administration, the pharmaceutical composition may be given in the form of a transdermal patch, such as a transdermal iontophoretic patch.

30 For parenteral administration, the pharmaceutical composition may be given as an injection or a continuous infusion (e.g. intravenously, intravascularly or subcutaneously). The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. For administration by injection these may take the form of a unit 35 dose presentation or as a multidose presentation preferably with an added preservative. Alternatively for parenteral administration the active ingredient may be in powder form for reconstitution with a suitable vehicle.

40 The compounds of the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic

materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

The EP₁ receptor compounds for use in the instant invention may be used in combination with other therapeutic agents, for example COX-2 inhibitors, such as celecoxib, deracoxib, rofecoxib, valdecoxib, parecoxib or COX-189; 5-lipoxygenase inhibitors; NSAID's, such as diclofenac, indomethacin, nabumetone or ibuprofen; leukotriene receptor antagonists; DMARD's such as methotrexate; adenosine A1 receptor agonists; sodium channel blockers, such as lamotrigine; NMDA receptor modulators, such as glycine receptor antagonists; gabapentin and related compounds; tricyclic antidepressants such as amitriptyline; neurone stabilising antiepileptic drugs; mono-aminergic uptake inhibitors such as venlafaxine; opioid analgesics; local anaesthetics; 5HT₁ agonists, such as triptans, for example sumatriptan, naratriptan, zolmitriptan, eletriptan, frovatriptan, almotriptan or rizatriptan; nicotinic acetyl choline (nACh) receptor modulators; glutamate receptor modulators, for example modulators of the NR2B ssubtype; EP₄ receptor ligands; EP₂ receptor ligands; EP₃ receptor ligands; EP₄ antagonists; EP₂ antagonists and EP₃ antagonists; cannabinoid receptor ligands; bradykinin receptor ligands and vanilloid receptor ligand. When the compounds are used in combination with other therapeutic agents, the compounds may be administered either sequentially or simultaneously by any convenient route.

Additional COX-2 inhibitors are disclosed in US Patent Nos. 5,474,995 US5,633,272; US5,466,823, US6,310,099 and US6,291,523; and in WO 96/25405, WO 97/38986, WO 98/03484, WO 97/14691, WO99/12930, WO00/26216, WO00/52008, WO00/38311, WO01/58881 and WO02/18374.

The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof together with a further therapeutic agent or agents.

The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention. The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.

When a compound of formula (I) or a pharmaceutically acceptable derivative thereof is used in combination with a second therapeutic agent active against the same disease state the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.

A proposed daily dosage of compounds of formula (I) or their pharmaceutically acceptable derivatives for the treatment of man is from 0.01 to 30 mg/kg body weight per day and more particularly 0.1 to 10 mg/kg body weight per day, calculated as the free base, which may be administered as a single or divided dose, for example one to four times per day

5 The dose range for adult human beings is generally from 8 to 2000 mg/day, such as from 20 to 1000 mg/day, preferably 35 to 200 mg/day, calculated as the free base.

The precise amount of the compounds of formula (I) administered to a host, particularly a human patient, will be the responsibility of the attendant physician. However, the dose

10 employed will depend on a number of factors including the age and sex of the patient, the precise condition being treated and its severity, and the route of administration.

No unacceptable toxicological effects are expected with compounds of the invention when administered in accordance with the invention.

15 All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

20 The following non-limiting Examples illustrate the preparation of pharmacologically active compounds of the invention.

EXAMPLES**ABBREVIATIONS:**

5 Bn (benzyl), Bu, Pr, Me, Et (butyl, propyl, methyl ethyl), DMSO (dimethyl sulfoxide), DCM (dichloromethane), DME (ethylene glycol dimethyl ether), DMF (N,N-dimethylformamide), EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide), EtOAc (ethyl acetate), EtOH (ethanol), HPLC (High pressure liquid chromatography), LCMS (Liquid chromatography/Mass spectroscopy), MDAP (Mass Directed Purification), MeOH (methanol), NMR (Nuclear Magnetic Resonance (spectrum)), Ph (phenyl), pTSA (para-toluene sulphonic acid), SPE (Solid Phase Extraction), TBAF (tetrabutylammonium fluoride), THF (tetrahydrofuran), s, d, t, q, m, br (singlet, doublet, triplet, quartet, multiplet, broad.)

10 NMR (Nuclear Magnetic Resonance (spectrum)), Ph (phenyl), pTSA (para-toluene sulphonic acid), SPE (Solid Phase Extraction), TBAF (tetrabutylammonium fluoride), THF (tetrahydrofuran), s, d, t, q, m, br (singlet, doublet, triplet, quartet, multiplet, broad.)

15 LCMS

- Column: 3.3cm x 4.6mm ID, 3um ABZ+PLUS
- Flow Rate: 3ml/min
- Injection Volume: 5 μ l
- Temp: RT
- UV Detection Range: 215 to 330nm
-

Solvents: A: 0.1% Formic Acid + 10mMolar Ammonium Acetate.
 B: 95% Acetonitrile + 0.05% Formic Acid

Gradient:	Time	A%	B%
	0.00	100	0
	0.70	100	0
	4.20	0	100
	5.30	0	100
	5.50	100	0

25 Mass Directed Autopreparation**Hardware:**

Waters 600 gradient pump

Waters 2767 inject/collector

30 Waters Reagent Manager

Micromass ZMD mass spectrometer

Gilson Aspec - waste collector

Gilson 115 post-fraction UV detector

Software:**35 Micromass Masslynx version 4.0**

Column

The column used is typically a Supelco LCABZ++ column whose dimensions are 20mm internal diameter by 100mm in length. The stationary phase particle size is 5 μ m.

Solvents:

5 A.: Aqueous solvent = Water + 0.1% Formic Acid
 B: Organic solvent = MeCN: Water 95:5 +0.05% Formic Acid
 Make up solvent = MeOH: Water 80:20 +50mMol Ammonium Acetate
 Needle rinse solvent = MeOH: Water: DMSO 80:10:10

10 The method used depends on the analytical retention time of the compound of interest. 15-minute runtime, which comprises a 10-minute gradient followed by a 5-minute column flush and re-equilibration step.

MDP 1.5-2.2 = 0-30% B

MDP 2.0-2.8 = 5-30% B

15 MDP 2.5-3.0 = 15-55% B

MDP 2.8-4.0 = 30-80% B


MDP 3.8-5.5 = 50-90% B

Flow rate:

flow rate 20ml/min.

20


PREPARATION OF INTERMEDIATES

[2-(Benzylxy)-phenyl]-carbamic acid 2-trimethylsilyl-ethyl ester

25 2-(Benzylxy)benzoic acid (5.064g, 22.2mmol), diphenylphosphoryl azide (7.2mL, 33.4mmol, 1.5eq) and triethylamine (4.6mL, 33.4mmol, 1.5eq) were heated in toluene (44mL, 0.5M) at 80°C for 30 minutes. Trimethylsilyl ethanol (6.4mL, 44.4mmol) was added and heating was continued for 24 hours (complete after 1hr). Upon cooling, the mixture was diluted with ethyl acetate and washed sequentially with 2M HCl and saturated sodium bicarbonate, dried (Na_2SO_4), filtered and concentrated. The residue was purified by chromatography on silica gel with iso-hexane containing ethyl acetate (1-3%) to yield the title compound (6.440g, 85%) as a colourless oil.
 30 ^1H NMR (CDCl_3) δ : 0.00 (9H, s), 0.94-1.05 (2H, m), 4.13-4.27 (2H, m), 5.04 (2H, s), 6.81-6.97 (3H, m), 7.15 (1H, s), 7.25-7.41 (5H, m), 8.06 (1H, br).

35

2-(Benzylxy)-aniline



1M TBAF (tetrabutylammonium fluoride) in THF (tetrahydrofuran) (12mL, 12.0mmol) was added to [2-(benzyloxy)-phenyl]-carbamic acid 2-trimethylsilyl-ethyl ester (2.081g, 6.1mmol). The solution was stirred at room temperature for 4 hours, then more 1M TBAF in THF (6ml, 6.0mmol) was added and stirring continued for 2.5 hours. The mixture was diluted with diethyl ether and washed with water, dried (Na_2SO_4), filtered and evaporated to yield the title compound (1.208g, 93%).

^1H NMR (CDCl_3) δ H: 3.80 (2H, br), 5.07 (2H, s), 6.66-6.76 (2H, m), 6.77-6.89 (2H, m), 7.29-7.47 (5H, m).

10


2-(Benzyl)-5-chloro-nitrobenzene



Benzyl bromide (10.7mL, 119.8 mmol), 4-chloro-2-nitrophenol (10.348g, 59.6mmol) and potassium carbonate (16.535g, mmol) were heated in DMF (N,N-dimethyl formamide) (60mL) at 60°C for 22 hours. Upon cooling, the mixture was diluted with diethyl ether and water. The layers were separated and the aqueous phase was extracted further with diethyl ether. The combined extracts were dried (Na_2SO_4), filtered and concentrated to yield the title compound (14.760g, 94%).


^1H NMR (CDCl_3) δ H: 5.26 (2H, s), 7.06 (1H, d, $J=9\text{Hz}$), 7.30-7.48 (6H, m), 7.85 (1H, $J=2\text{Hz}$).

2-(Benzyl)-5-chloro aniline




Zinc powder (13.200g) was added slowly (heat evolved) to 2-(benzyl)-5-chloro-nitrobenzene (5.022g, 19.1mmol) in acetic acid (95mL) at room temperature. The mixture was stirred overnight then filtered and evaporated. 2M sodium hydroxide and EtOAc were added to the residue. The layers were separated and the aqueous phase was extracted further with ethyl acetate. The combined extracts were dried (Na_2SO_4), filtered and evaporated to yield the title compound (4.420g, 99%).

^1H NMR (CDCl_3) δ H: 6.63 (1H, dd, $J=2\text{Hz}$, $J=9\text{Hz}$), 6.69 (1H, $J=2\text{Hz}$), 6.73 (1H, d, $J=9\text{Hz}$), 7.30-7.47 (5H, m).

2-(Benzylxy)-5-bromo-nitrobenzene


The title compound was prepared in an analogous fashion to 2-(benzylxy)-5-chloro-nitrobenzene, except 4-chloro-2-nitrophenol was replaced with 4-bromo-2-nitrophenol.

5

2-(Benzylxy)-5-bromo-aniline

The title compound was prepared in an analogous fashion to 2-(benzylxy)-5-chloro-aniline, except that 2-(benzylxy)-5-chloro-nitrobenzene was replaced with 2-(benzylxy)-5-bromo-nitrobenzene.


10

3-(4-Oxo-pentanoyl)-benzoic acid methyl ester

Methyl vinyl ketone (0.64ml, 7.7mmol, 1.2eq), 3-formylbenzoate (1.048g, 6.4mmol), triethylamine (1.3ml, 9.6mmol, 1.5eq) and 3-ethyl-5-(2-hydroxyethyl)-4-methylthiazolium bromide (355mg, 1.4mmol, 0.15eq) were heated at reflux in ethanol (2.2ml, 3M) for 4 hours. Upon cooling and dilution with ethyl acetate, the mixture was washed sequentially with saturated ammonium chloride and saturated sodium bicarbonate, dried (Na_2SO_4), filtered and evaporated. The residue was purified by chromatography on silica gel with isohexane containing a gradient of ethyl acetate (20-40%) to yield the title compound (1.324g, 89%).

^1H NMR (CDCl_3) δ H: 2.28 (3H, s), 2.92 (2H, t, $J=6\text{Hz}$), 3.31 (2H, t, $J=6\text{Hz}$), 3.96 (3H, s), 7.56 (1H, t, $J=8\text{Hz}$), 8.18 (1H, dt, $J=1\text{Hz}$, $J=8\text{Hz}$), 8.24 (1H, dt, $J=1\text{Hz}$, $J=8\text{Hz}$), 8.63 (1H, s).

25

Example 1: 3-[1-[2-(Benzylxy)-phenyl]-5-methyl-1H-pyrrol-2-yl]-benzoic acida) 3-[1-[2-(Benzylxy)-phenyl]-5-methyl-1H-pyrrol-2-yl]-benzoic acid methyl ester

3-(4-Oxo-pentanoyl)-benzoic acid methyl ester (250mg, 1.1mmol), 2-(benzylxy)-aniline hydrochloride (240mg, 1.0mmol) and triethylamine (0.14ml, 1.0mmol) were heated in toluene (5ml) in a reacti-vial at 120°C for 24 hours. Upon cooling, the mixture was diluted

with ethyl acetate and washed sequentially with 2M HCl and saturated sodium bicarbonate, dried (Na_2SO_4), filtered and concentrated. The residue was purified by chromatography on silica gel with iso-hexane containing an ethyl acetate gradient (5-10%) to yield the title compound (240mg, 57%).

5 ^1H NMR (CDCl_3) δ H: 2.09 (3H, s), 3.81 (3H, s), 4.92 (1H, d, $J=13\text{Hz}$), 5.03 (1H, d, $J=13\text{Hz}$), 6.13 (1H, d, $J=3.5\text{Hz}$), 6.45 (1H, d, $J=3.5\text{Hz}$), 6.91-7.02 (2H, m), 7.03-7.35 (9H, m's excess), 7.72 (1H, d, $J=6\text{Hz}$), 7.83 (1H, s).


10 b) 3-[1-[2-(Benzylxy)-phenyl]-5-methyl-1H-pyrrol-2-yl]-benzoic acid



3-[1-[2-(Benzylxy)-phenyl]-5-methyl-1H-pyrrol-2-yl]-benzoic acid methyl ester (129mg, 0.3mmol) was heated at 90°C in a mixture of ethanol (2ml) and 2M sodium hydroxide (1ml) in a reacti-vial for 4 hours. The mixture was then cooled, diluted with ethyl acetate and washed with 2M HCl, dried (Na_2SO_4), filtered and concentrated to yield the title compound (120mg, 96%).
 15 LC/MS Rt=3.74 min [MH^+] 384, [MH^-] 382.

20 **Example 2: 3-[1-[2-(Benzylxy)-5-chloro-phenyl]-5-methyl-1H-pyrrol-2-yl]-benzoic acid**

a) 3-[1-[2-(Benzylxy)-5-chloro-phenyl]-5-methyl-1H-pyrrol-2-yl]-benzoic acid methyl ester



25 3-(4-Oxo-pentanoyl)-benzoic acid methyl ester (206mg, 0.9mmol), (2-benzylxy)-5-chloro-aniline (254mg, 1.1mmol) and pTSA (22mg, cat.) were heated at reflux in toluene (8.8ml) for 3.5 hours. Upon cooling, the mixture was diluted with ethyl acetate and washed sequentially with 2M HCl and saturated sodium bicarbonate, dried (Na_2SO_4), filtered and concentrated. The residue was purified by chromatography on silica gel with iso-hexane containing an ethyl acetate gradient (3-5%) to yield the title compound (280mg, 74%).
 30 LC/MS Rt=4.06 min [MH^+] 432, 434.

35 ^1H NMR (CDCl_3) δ H: 2.09 (3H, s), 3.83 (3H, s), 4.88 (1H, d, $J=12.5\text{Hz}$), 5.00 (1H, d, $J=12.5\text{Hz}$), 6.12 (1H, d, $J=3\text{Hz}$), 6.43 (1H, d, $J=3\text{Hz}$), 6.87 (1H, d, $J=9\text{Hz}$), 7.02-7.10 (2H, m), 7.16-7.29 (7H, m's excess), 7.76 (1H, d, $J=7\text{Hz}$), 7.83 (1H, s).

LC/MS Rt=4.06 min [MH^+] 432, 434.

35 b) 3-[1-[2-(Benzylxy)-5-chloro-phenyl]-5-methyl-1H-pyrrol-2-yl]-benzoic acid




3-{1-[2-(Benzyl)-5-chloro-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid methyl ester (280mg, 0.7mmol) was heated at reflux in a mixture of ethanol (6ml) and 2M sodium hydroxide (3ml) for 2.5 hours. The mixture was then cooled, diluted with ethyl acetate and washed with 2M HCl, dried (Na_2SO_4), filtered and concentrated to yield the title compound (268mg, 99%).

¹H NMR (CDCl_3) δ H: 2.09 (3H, s), 4.90 (1H, d, $J=13\text{Hz}$), 5.01 (1H, d, $J=13\text{Hz}$), 6.13 (1H, d, $J=4\text{Hz}$), 6.44 (1H, d, $J=4\text{Hz}$), 6.88 (1H, d, $J=9\text{Hz}$), 7.05-7.11 (2H, m), 7.18 (1H, d, $J=3\text{Hz}$), 7.02-7.33 (6H, m's excess), 7.83 (1H, d, $J=8\text{Hz}$), 7.90 (1H, s).

LC/MS Rt=3.88 [MH⁺] 418 & 420, [MH⁻] 416 & 418.

Example 3: 3-{1-[2-(Benzyl)-5-bromo-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid

a) 3-{1-[2-(Benzyl)-5-bromo-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid methyl ester



The title compound was prepared in an analogous fashion to 3-{1-[2-(benzyl)-5-chloro-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid methyl ester except that 2-(benzyl)-5-chloroaniline was replaced by 2-(benzyl)-5-bromo aniline and the mixture was heated at reflux for 2 hours.

b) 3-{1-[2-(Benzyl)-5-bromo-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid




25 The title compound was prepared in an analogous fashion to 3-{1-[2-(benzyl)-5-chloro-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid except that 3-{1-[2-(benzyl)-5-chloro-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid methyl ester was replaced by 3-{1-[2-(Benzyl)-5-bromo-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid methyl ester.

LC/MS Rt=3.90 [MH⁺] 462, [MH⁻] 460.

30

Example 4: 3-{5-[2-(Benzyl)-phenyl]-1H-pyrazol-1-yl}-benzoic acid


a) 4-[2-(Benzyl)-phenyl]-2,4-dioxobutyric acid methyl ester



2-Benzylxyacetophenone (2.230g, 9.87 mmol) was stirred at room temperature in MeOH (20mL) with sodium methoxide (1.074g) and dimethyl oxalate (2.379g). After 24 hours the mixture was quenched with saturated ammonium chloride and extracted with ethyl acetate.

5 The extracts were dried (Na_2SO_4), filtered and evaporated. The residue was chromatographed on silica gel with hexane containing ethyl acetate (5-20%) to yield the title compound, 2.490g (81%).


b) 3-[3-[(Methoxy)carbonyl]-5-[2-(benzyloxy)-phenyl]-1H-pyrazol-1-yl]-benzoic acid



10 4-[2-(Benzylxy)-phenyl]-2,4-dioxo-butyric acid methyl ester (312mg, 1mmol) and 3-hydrazinobenzoic acid (167mg, 1.1mmol) were dissolved in methanol (5ml) and the solution heated to reflux for 1 hour. After cooling, the solvent was evaporated and the residue partitioned between dichloromethane and water. The organic layer was dried (MgSO_4), evaporated to dryness and dissolved in diethyl ether. A cream solid crystallised and was filtered, washed with diethyl ether and dried in vacuo to give the title compound (330mg).

15 LC/MS $\text{Rt}=3.46$ $[\text{MH}^+]$ 428. (contains ca. 20% $[\text{MH}^+]$ 446).

20 c) 3-[3-Carboxy-5-[2-(benzyloxy)-phenyl]-1H-pyrazol-1-yl]-benzoic acid




25 3-[3-[(Methoxy)carbonyl]-5-[2-(benzyloxy)-phenyl]-1H-pyrazol-1-yl]-benzoic acid (330mg, 0.77mmol) was dissolved in ethanol (2ml) and 2M sodium hydroxide solution (1ml) added. The mixture was heated to reflux for 2 hours. After cooling, the ethanol was evaporated and the residue diluted with water and extracted with diethyl ether. The aqueous layer was acidified with 2M hydrochloric acid solution and extracted with diethyl ether (x2). The combined organic layers were washed with water, dried (MgSO_4) and evaporated. The

residue was triturated with diethyl ether and the title compound filtered and dried in vacuo (205mg). LC/MS Rt=3.65 [MH⁺] 415.

d) 3-[5-[2-(Benzylxy)-phenyl]-1H-pyrazol-1-yl]-benzoic acid

5




3-[3-Carboxy-5-[2-(benzylxy)-phenyl]-1H-pyrazol-1-yl]-benzoic acid

(50mg, 0.121mmol) was heated under nitrogen at 190-220°C for 15 minutes. The product was purified by preparative HPLC and trituration with isohexane containing a trace of dichloromethane to give the title compound as a cream solid. (12.5mg)
¹H NMR (CDCl₃) δH: 4.75 (2H, s), 6.51 (1H, s), 6.86 (1H, d, J=8Hz), 6.96-6.98 (2H, m), 7.00-7.04 (1H, t, J=5Hz), 7.23-7.41 (7H, m), 7.89 (1H, s), 7.93 (1H, d, J=3Hz), 8.04 (1H, s).
 LC/MS Rt=3.45 [MH⁺] 371.

Example 5: 3-[5-[2-(Benzylxy)-5-chloro-phenyl]-1H-pyrazol-1-yl]-benzoic acid

a) 4-[2-(Benzylxy)-5-chloro-phenyl]-2,4-dioxobutyric acid methyl ester




20

The title compound was prepared in a similar manner to 4-[2-(benzylxy)-phenyl]-2,4-dioxobutyric acid methyl ester starting from 5-chloro-2-benzylxyacetophenone.
 LC/MS Rt 3.79 min, [MH⁺] 345, 347.

25

b) 3-[3-[(Methyloxy)carbonyl]-5-[2-(benzylxy)-5-chloro-phenyl]-1H-pyrazol-1-yl]-benzoic acid




The title compound was prepared in a similar manner to 3-{3-[(methyloxy)carbonyl]-5-[2-(benzyloxy)-phenyl]-1H-pyrazol-1-yl}-benzoic acid starting from 4-[2-(benzyloxy)-5-chlorophenyl]-2,4-dioxobutyric acid methyl ester.

LC/MS Rt 3.63 min, [MH⁺] 463, 465.

5

c) 3-{3-Carboxy-5-[2-(benzyloxy)-5-chloro-phenyl]-1H-pyrazol-1-yl}-benzoic acid




The title compound was prepared in a similar manner to 3-{3-Carboxy-5-[2-(benzyloxy)-phenyl]-1H-pyrazol-1-yl}-benzoic acid starting from 3-{3-[(methyloxy)carbonyl]-5-[2-(benzyloxy)-5-chlorophenyl]-1H-pyrazol-1-yl}-benzoic acid.

10

LC/MS Rt 4.03 min, [MH⁺] 449, 451.

d) 3-{5-[2-(BenzylOxy)-5-chloro-phenyl]-1H-pyrazol-1-yl}-benzoic acid




15

The title compound was prepared in a similar manner to 3-{5-[2-(benzyloxy)-phenyl]-1H-pyrazol-1-yl}-benzoic acid starting from 3-{3-carboxy-5-[2-(benzyloxy)-5-chlorophenyl]-1H-pyrazol-1-yl}-benzoic acid.

¹H NMR (CDCl₃) δH: 4.70 (2H, s), 6.50 (1H, s), 6.77 (1H, d, J=5Hz), 6.92 (2H, m), 7.23-7.39 (7H, m), 7.83 (1H, s), 7.96 (1H, d, J=3Hz), 8.03 (1H, s).

Example 6: 3-{3-[2-(BenzylOxy)-5-chloro-phenyl]-pyrazin-2-yl}-benzoic acid

a) 2-[2-(BenzylOxy)-5-chloro]-3-chloro-pyrazine



25


2,3-Dichloropyrazine (255mg, 1.71 mmol), 2-(benzyloxy)-5-chloro-phenylboronic acid (450mg, 1.71 mmol) and sodium carbonate (139mg) were stirred in DME (ethylene glycol dimethyl ether) -water (1:1, 10 mL) under nitrogen for 20 minutes, then

tetrakis(triphenylphosphine)palladium(0) (100mg) was added and the mixture heated at

reflux for 20 hours. Upon cooling, saturated ammonium chloride was added and the resultant mixture was extracted with DCM (x 2). The combined extracts were dried (MgSO_4), filtered and evaporated. The residue was chromatographed on silica gel with cyclohexane containing ethyl acetate (5-100%) to yield the title compound (448mg, 80%).

5 LC/MS R_t = 3.47 min, [MH⁺] 331.

b) 3-[3-[2-(BenzylOxy)-5-chloro-phenyl]-pyrazin-2-yl]-benzoic acid




10 2-[2-(BenzylOxy)-5-chloro-phenyl]-3-chloro-pyrazine (200mg, 0.61mmol), 3-carboxyphenyl boronic acid (101mg, 0.61mmol) and sodium carbonate (51mg) were stirred in DME-water (1:1, 4mL) for 30 minutes then tetrakis(triphenylphosphine)palladium(0) (40mg) was added and the mixture heated at reflux for 18 hours. Upon cooling to room temperature saturated ammonium chloride was added and the resultant mixture was extracted with DCM (x 2).
15 The combined extracts were dried (MgSO_4), filtered and evaporated. The residue was purified by MDAP to give the title compound (10mg).

LC/MS R_t 3.55 min, [MH⁺] 417.


20 Example 7: 3-[4-[2-(BenzylOxy)-5-Chloro-phenyl]-2-oxo-2,5-dihydro-furan-3-yl]-benzoic acid

a) 3-Bromo-4-[2-(benzylOxy)-5-chloro-phenyl]-2(5H)-furanone




25 2-(BenzylOxy)-5-chloro-phenylboronic acid (1.58g, 6mmol) and 3,4-dibromo-2(5H)-furanone (1.21g, 5mmol) were dissolved in tetrahydrofuran (50ml) under nitrogen and bis(acetonitrile)dichloropalladium(II) (130mg, 0.5mmol), triphenylarsine (310mg, 1mmol) and silver (II) oxide (3.48g, 15mmol) added. The mixture was stirred and heated to 50°C for 16 hours. Ethyl acetate (125ml) was added and the mixture filtered through a pad of Kieselguhr. The filtrate was washed with water (x2), dried (MgSO_4) and evaporated. The residue was purified by chromatography on silica gel, eluting with 5-20% ethyl acetate in isohexane. The product was triturated with diethyl ether/isoctane and the solid filtered and dried in vacuo to give the title compound. (738mg)

30 ^1H NMR (CDCl_3) δ H: 5.09 (2H, s), 5.16 (2H, s), 7.00 (1H, d, $J=9\text{Hz}$), 7.34-7.42 (6H, m), 7.79 (1H, d, $J=2.5\text{Hz}$).

b) 3-[4-[2-(BenzylOxy)-5-Chloro-phenyl]-2-oxo-2,5-dihydro-furan-3-yl]-benzoic acid


5 3-Bromo-4-[2-(benzylOxy)-5-chloro-phenyl]-2(5H)-furanone (95mg, 0.25mmol) and 3-carboxyphenylboronic acid (50mg, 0.3mmol) were dissolved in tetrahydrofuran (4ml) under nitrogen and bis(acetonitrile)dichloropalladium(II) (7mg, 0.025mmol), triphenylarsine (16mg, 0.05mmol) and silver (II) oxide (174mg, 0.75mmol) added. The mixture was stirred and heated to 80°C for 8 hours then left stirring at room temperature for 72 hours. Ethyl acetate (20ml) was added and the mixture filtered through a pad of Kieselguhr. The filtrate was washed with water (x2), dried (MgSO_4) and evaporated. The residue was purified by chromatography on silica gel, eluting with 5-20% ethyl acetate in isohexane then 80% ethyl acetate in isohexane. The product was further purified by preparative HPLC to give the title compound (10.5mg)

10 15 LC/MS Rt 3.52 min, $[\text{MH}^+]$ 419.

Example 8: 3-[3-[2-(BenzylOxy)-5-chloro-phenyl]-2-oxo-2,5-dihydro-furan-4-yl]-benzoic acida) 3-(3-Bromo-2-oxo-2,5-dihydrofuran-4-yl)-benzoic acid tert-butyl ester

20 25 3-(tert-Butoxycarbonyl)-phenylboronic acid (133mg, 0.6mmol) and 3,4-dibromo-2(5H)-furanone (121mg, 0.5mmol) were dissolved in tetrahydrofuran (5ml) under nitrogen and bis(acetonitrile)dichloropalladium(II) (13mg, 0.05mmol), triphenylarsine (31mg, 0.1mmol) and silver (II) oxide (348mg, 1.5mmol) added. The mixture was stirred and heated to 50°C for 4 hours. Ethyl acetate (20ml) was added and the mixture filtered through a pad of Kieselguhr. The filtrate was washed with water (x2), dried (MgSO_4) and evaporated. The residue was purified by chromatography on silica gel, eluting with 5-20% ethyl acetate in isohexane to give the title compound. (60mg).


30 LC/MS Rt 3.41 min, $[\text{MH}^+]$ 339,341.

b) 3-[3-[2-(BenzylOxy)-5-chloro-phenyl]-2-oxo-2,5-dihydro-furan-4-yl]-benzoic acid tert-butyl ester

3-(3-bromo-2-oxo-2,5-dihydrofuran-4-yl)-benzoic acid tert-butyl ester (60mg, 0.177mmol) and 2-(benzyloxy)-5-chlorophenylboronic acid (56mg, 0.212mmol) were dissolved in tetrahydrofuran (2ml) under nitrogen and bis(acetonitrile)dichloropalladium(II) (5mg, 0.0177mmol), triphenylarsine (9mg, 0.035mmol) and silver (II) oxide (103mg, 0.531mmol) added. The mixture was stirred and heated to 60°C for 16 hours. The mixture was then filtered through a pad of Kieselguhr and washed with ethyl acetate. The filtrate was evaporated. The residue was dissolved in tetrahydrofuran (2ml) under nitrogen and 2-(benzyloxy)-5-chlorophenylboronic acid (28mg, 0.106mmol), bis(acetonitrile)dichloropalladium(II) (2.5mg, 0.0088mmol), triphenylarsine (4.5mg, 0.018mmol) and silver (II) oxide (52mg, 0.265mmol) added. The mixture was stirred and heated to 60°C for 16 hours. Ethyl acetate (10ml) was added and the mixture filtered through a pad of Kieselguhr. The filtrate was washed with water (x2), dried (MgSO_4) and evaporated. The residue was purified by chromatography on silica gel, eluting with 5-15% ethyl acetate in isohexane to give the title compound. (37mg)

LC/MS Rt 3.90 min, $[\text{MH}^+]$ 475, 477.

c) 3-[3-[2-(BenzylOxy)-5-chloro-phenyl]-2-oxo-2,5-dihydro-furan-4-yl]-benzoic acid



3-[3-[2-(BenzylOxy)-5-chloro-phenyl]-2-oxo-2,5-dihydro-furan-4-yl]-benzoic acid tert-butyl ester (37mg, 0.078mmol) was dissolved in dichloromethane (3ml) and trifluoroacetic acid (1ml) added. The mixture was stirred at room temperature for 16 hours. The mixture was evaporated and the residue re-evaporated from toluene. The crude product was purified by preparative HPLC and triturated with diethyl ether. Filtration gave the title compound as an off-white solid. (10mg).

LC/MS Rt 3.45 min, $[\text{MH}^+]$ 419, 421.

PREPARATION OF INTERMEDIATES

2-(BenzylOxy)-5-chloro-iodobenzene

4-Chloro-2-iodophenol (57g, 0.22mol) was dissolved in acetonitrile (500ml), caesium carbonate (72.6g, 0.22mol.) was added slowly giving rise to an exotherm (19-24°C) over 30 minutes. The reaction mixture was then kept at 24°C for a further 5 hours. The reaction mixture was then stirred at 40°C for 4 hours, then stirred at room temperature over night. The reaction mixture was filtered and evaporated down to a pink/brown solid. After trituration with water (200ml) the suspension was filtered and recrystallised from hexane (200ml) giving the title compound 50.2g, 65% yield. A second crop gave a further 22.7g. Total yield after drying 88%.


2-(BenzylOxy)-5-chloro-phenylboronic acid

2-(Benzylxy)-5-chloro-iodobenzene (5g 0.0145 mol) in diethyl ether/tetrahydrofuran (100:30) was cooled to -100°C . *n*-Butyl lithium, 1.6M solution in hexanes (10mL, 0.016 mol) was added dropwise over 15min under nitrogen. The reaction mixture was then allowed to rise to -70°C for 1h. Triethylborate (9mL, 0.03 mol) was added dropwise under nitrogen. The cooling bath was then removed and the reaction mixture was stirred at room temperature overnight. The reaction mixture was then quenched with 2N hydrochloric acid (40mL) and stirred vigorously at room temperature for 1h. The product was then extracted with ethyl acetate, dried over magnesium sulphate and evaporated down to an oil.

5 Purification was carried out on silica gel with diethyl ether / iso-hexane (50:50) to give the title compound (2.8g, 74% yield).

10

Ethyl 3-(3-bromopyridin-4-yl)benzoate



15 1.6M butyllithium in hexanes (20.2 ml, 32.32 mmol) was added over 5 minutes to a solution of diisopropylamine (3.27g, 32.35 mmol) in anhydrous THF (70ml) at -78°C under nitrogen and stirred for 10 minutes then allowed to warm to room temperature. This mixture was then added to a solution of 3-bromopyridine (4.26g, 27.00 mmol) in THF (50 ml) at -95°C over 15 minutes. After stirring for 25 minutes 0.5M zinc chloride solution in THF (53.9 ml, 26.95 mmol) was added over 15 minutes and the mixture allowed to warm to room temperature. Ethyl 3-iodobenzoate (2.76g, 10 mmol) and


20 tetrakis(triphenylphosphine)palladium(0) (570mg, 0.5 mmol) were added and the mixture refluxed for 2.5 hours then cooled and evaporated to dryness. The residue was dissolved in ether/1M sodium hydroxide solution and the organic phase was dried (magnesium sulphate), evaporated and purified by chromatography on silica eluting with

25 ethyl acetate/iso-hexane (1:4) then rechromatographed eluting with methanol/dichloromethane (1:199). Recrystallisation from iso-hexane gave the title compound (1.36g) as a white solid.

LC/MS $t=3.26$, $[\text{MH}^+]$ 307.9

30

3-[3-(2-(Benzylxy)-5-chloro-phenyl)-pyridin-4-yl]-benzoic acid ethyl ester




A mixture of ethyl 3-(3-bromopyridin-4-yl)benzoate (156mg, 0.51 mmol), 2-(benzyloxy)-5-chlorophenylboronic acid (157mg, 0.6 mmol), potassium carbonate (568mg, 4.11 mmol) and tetrakis(triphenylphosphine)palladium(0) (66mg, 0.057 mmol) was stirred and heated at 90°C in 1:1 toluene/ethanol (5 ml) for 16 hours then cooled to room temperature and

5 diluted with ether/water. The organic phase was dried (magnesium sulphate), evaporated and purified by chromatography on silica eluting with ethyl acetate/iso-hexane (1:3) to give the title compound (179mg) as a colourless gum.

LC/MS t=3.79, [MH+] 444.0, 446.0


10 3-[3-[2-(BenzylOxy)-phenyl]-pyridin-4-yl]-benzoic acid ethyl ester



The title compound was prepared using an analogous procedure to that used for the preparation of 3-[3-[2-(benzyloxy)-5-chloro-phenyl]-pyridin-4-yl]-benzoic acid ethyl ester but using 2-(benzyloxy)phenylboronic acid instead of 2-(benzyloxy)-5-chlorophenylboronic acid.

LC/MS t=3.62, [MH+] 410.1


4-[2-(BenzylOxy)-5-chloro-phenyl]-3-bromopyridine



20 The title compound was prepared using an analogous procedure to that used for the preparation of ethyl 3-(3-bromopyridin-4-yl)benzoate but using 2-(benzyloxy)-5-chloro-iodobenzene instead of ethyl 3-iodobenzoate.


LC/MS t=3.71, [MH+] 375.9, 377.8

25 3-[4-[2-(BenzylOxy)-5-chloro-phenyl]-pyridin-3-yl]-benzoic acid ethyl ester




30 The title compound was prepared using an analogous procedure to that used for the preparation of 3-[3-[2-(benzyloxy)-5-chloro-phenyl]-pyridin-4-yl]-benzoic acid ethyl ester but using 4-[2-(benzyloxy)-5-chlorophenyl]-3-bromopyridine instead of ethyl 3-(3-bromopyridin-4-yl)benzoate and 3-(ethoxycarbonyl)-phenylboronic acid instead of 2-(benzyloxy)-5-chlorophenylboronic acid.

LC/MS t=3.80, [MH+] 444.0, 446.0.

3-[2-(BenzylOxy)-5-chloro-phenyl]-2-bromopyridine

Was prepared sing an analogous procedure to that used for the preparation of 3-(3-bromopyridin-4-yl)-benzoic acid ethyl ester but using 2-bromopyridine instead of 3-bromopyridine and 2-(benzylOxy)-5-chloro-iodobenzene instead of ethyl 3-iodobenzoate.

5 LC/MS t=3.69, [MH⁺] 375.9, 377.9

3-[3-[2-(BenzylOxy)-5-chloro-phenyl]-pyridin-2-yl]-benzoic acid ethyl ester


10

The title compound was prepared sing an analogous procedure to that used for the preparation of 3-[3-[2-(benzylOxy)-5-chloro-phenyl]-pyridin-4-yl]-benzoic acid ethyl ester but using 3-[2-(benzylOxy)-5-chloro-phenyl]-2-bromopyridine instead of ethyl 3-(3-bromopyridin-4-yl)-benzoate and 3-(ethoxycarbonyl)phenylboronic acid instead of 2-(benzylOxy)-5-chloro-phenylboronic acid.

15 LC/MS t=3.85, [MH⁺] 444.1

Example 9: 3-[3-[2-(BenzylOxy)-5-chloro-phenyl]-pyridin-4-yl]-benzoic acid

20



25

A solution of 3-[3-[2-(benzylOxy)-5-chloro-phenyl]-pyridin-4-yl]-benzoic acid ethyl ester (175mg, 0.39 mmol) in ethanol (6 ml) and 2M sodium hydroxide (2 ml) was left at room temperature for 3 hours. The solvent was evaporated and the residue dissolved in water and washed with ether. The aqueous phase was acidified with acetic acid and extracted with ethyl acetate which was dried (magnesium sulphate) evaporated and the residue triturated with ether to give the title compound (136mg) as an off-white solid.

LC/MS t=3.44, [MH⁺] 416.0, 418.0.

30 The following compounds were prepared by an analogous hydrolysis procedure from an appropriate ester intermediate.


EXAMPLES	COMPOUND NAME	LC/MS
----------	---------------	-------

Example 10	3-{3-[2-(BenzylOxy)-phenyl]-pyridin-4-yl}-benzoic acid	t=3.22 [MH+] 382.1
Example 11	3-{4-[2-(BenzylOxy)-5-chloro-phenyl]-pyridin-3-yl}-benzoic acid	t=3.49 [MH+] 416.0, 418.0
Example 12	3-{3-[2-(BenzylOxy)-5-chloro-phenyl]-pyridin-2-yl}-benzoic acid	t=3.57 [MH+] 416.1, 418.1

General procedure A**A (i) 4-(BenzylOxy)benzotrifluoride**

5 A solution of 4-hydroxybenzotrifluoride (8.55g, 52.78mmol) in acetone (200ml) was treated with benzyl bromide (9.87g, 6.86ml, 58.05mmol) and potassium carbonate (10.94g, 79.16mmol). The mixture was stirred and heated to reflux under nitrogen for 3 hours. After cooling, diethyl ether (400ml) and water (400ml) were added. The layers were separated and the aqueous phase re-extracted with diethyl ether (100ml). The combined organic layers were washed with water, dried (MgSO_4) and the solvent removed *in vacuo* to leave the title compound (12.71g, 95%) as a white solid.


10 ^1H NMR (CDCl_3) δ H: 5.11 (2H, s), 7.03 (2H, d, J = 9Hz), 7.34-7.44 (5H, m), 7.55 (2H, d, J = 9Hz).

15 A (ii) 4-(BenzylOxy)-3-iodobenzotrifluoride

20 A solution of 4-(benzylOxy)benzotrifluoride (12.71g, 50.4mmol) in acetonitrile (300ml) was stirred under nitrogen and 1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (17.75g, 50.4mmol) and iodine (6.4g, 25.2mmol) added. The mixture was stirred at room temperature for 88h. The solvent was evaporated and the residue partitioned between ethyl acetate (400ml) and water (400ml). The organic layer was washed with water, dried (MgSO_4) and evaporated to an orange oil which was purified by flash chromatography on silica gel with 5% ethyl acetate in isohexane as eluant to give the title compound as an orange oil (15.07g, 79%).


25 ^1H NMR (CDCl_3) δ H: 5.21 (2H, s), 6.89 (1H, d J = 9Hz), 7.32-7.55 (6H, m), 8.04 (1H, d, J = 2Hz).

A (iii): 2-(BenzylOxy)-5-(trifluoromethyl)-benzeneboronic acid




A solution of 4-(benzyloxy)-3-iodobenzotrifluoride (15.07g, 39.85mmol) in tetrahydrofuran (200ml) was cooled to -40°C with stirring under nitrogen. 2M isopropylmagnesium chloride (200ml) was added dropwise and the mixture stirred at -40°C in diethyl ether (39.85ml, 79.7mmol) was added dropwise and the mixture stirred at -40°C for 40 minutes, then cooled to -75°C . Trimethyl borate (8.3g, 9.2ml, 79.7mmol) was added at -75°C over 10 minutes and the reaction stirred and allowed to reach 0°C over 1h. 1M hydrochloric acid (200ml) was added and the mixture stirred vigorously for 1h. The layers were separated and the aqueous layer extracted with diethyl ether (100ml). The combined organic layers were washed with water, dried (MgSO_4) and evaporated. The residue was 5 flash chromatographed on silica gel with 5-20% ethyl acetate in isohexane as eluant to give the title compound (7.71g, 65%) as a white solid.
 10 ^1H NMR (CDCl_3) δ H: 5.20 (2H, s), 5.79 (2H, s), 7.05 (1H, d, $J = 9\text{Hz}$), 7.39-7.44 (5H, m), 7.68 (1H, dd $J = 2\text{Hz}$, $J = 9\text{Hz}$), 8.15 (1H, d, $J = 2\text{Hz}$).

15 4-(4-Fluorobenzyloxy)-benzotrifluoride




Prepared by general procedure A(i) but using 4-fluorobenzyl bromide instead of benzyl bromide.
 1 ^1H NMR (CDCl_3) δ H: 5.07 (2H, s), 7.02 (2H, d, $J = 9\text{Hz}$), 7.07-7.11 (2H, m), 7.39-7.42 (2H, m), 7.52 (2H, d, $J = 9\text{Hz}$).

20 2-(4-Fluorobenzyloxy)-5-(trifluoromethyl)-iodobenzene



Prepared by general procedure A(ii) but using 4-(4-fluorobenzyloxy)-benzotrifluoride instead of 4-(benzyloxy)benzotrifluoride.
 25 ^1H NMR (CDCl_3) δ H: 5.16 (2H, s), 6.88 (1H, d, $J = 9\text{Hz}$), 7.08-7.13 (2H, m), 7.44-7.48 (2H, m), 7.54-7.57 (1H, dd, $J = 2\text{Hz}$, $J = 9\text{Hz}$), 8.04 (1H, d, $J = 2\text{Hz}$).


2-(4-Fluorobenzyloxy)-5-(trifluoromethyl)-benzeneboronic acid



Prepared by general procedure A(iii) but using 4-(4-fluorobenzyloxy)-3-iodobenzotrifluoride instead of 4-(benzyloxy)-3-iodobenzotrifluoride.

5 ^1H NMR (DMSO d_6) δ H: 5.22 (2H, s), 7.20-7.26 (3H, m), 7.54-7.58 (2H, m), 7.71 (1H, d, J = 9Hz), 7.75 (1H, s), 8.03 (2H, s).


4-(2,4-Difluorobenzyloxy)-benzotrifluoride



10 Prepared by general procedure A(i) but using 2,4-difluorobenzyl bromide instead of benzyl bromide.

^1H NMR (CDCl₃) δ H: 5.12 (2H, s), 6.89 (2H, dt, J = 2Hz, J = 9Hz), 7.02-7.05 (2H, d, J = 9Hz), 7.33-7.49 (1H, q, J = 8Hz, J = 15Hz), 7.56 (2H, d, J = 9Hz)


15 4-(2,4-Difluorobenzyloxy)-5-iodobenzotrifluoride



Prepared by general procedure A(ii) but using 4-(2,4-difluorobenzyloxy)benzotrifluoride instead of 4-(benzyloxy)benzotrifluoride.


20 ^1H NMR (CDCl₃) δ H: 5.21 (2H, s), 6.84-6.95 (3H, m), 7.55-7.65 (2H, m), 8.04 (1H, s)

2-(2,4-Difluorobenzyloxy)-5-(trifluoromethyl)-benzeneboronic acid




25 Prepared by general procedure A(iii) but using 4-(2,4-difluorobenzyloxy)-3-iodobenzotrifluoride instead of 4-(benzyloxy)-3-iodobenzotrifluoride.

^1H NMR (DMSO d_6) δ H: 5.26 (2H, s), 7.16 (1H, dt, J = 2Hz, J = 9Hz) 7.27 (1H, d, J = 9Hz), 7.33 (1H, dt, J = 2Hz, J = 9Hz), 7.68-7.75 (3H, m), 8.01 (2H, s).

3-iodo-5-nitrobenzoic acid


5 A solution of sodium nitrite (1.66g, 24mmol) was added over 10min. to a stirred suspension of 3-amino-5-nitrobenzoic acid (3.64g, 20mmol) in 10ml of conc. HCl at 0°C. Stirred for 1h then added in portions over 2min. to a stirred solution of potassium iodide (8.3g, 50mmol) in 30ml of water at 0°C. The mixture was then allowed to warm to room temperature over 2h and extracted with ethyl acetate. The organic layer was washed with sodium thiosulphate solution, dried and evaporated. The residue was purified by chromatography on a silica gel with 10% methanol in ethyl acetate, as eluant, to give the title compound as a red solid.

10 ^1H NMR (DMSO d_6) δ H: 8.55 (1H, s), 8.57 (1H, s), 8.71 (1H, s).

ethyl 3-iodo-5-nitrobenzoate

15 3-iodo-5-nitrobenzoic acid (9.3g, 0.0317mol) and thionyl chloride (20ml) were heated to reflux for 3h. After cooling, the solvent was removed *in vacuo* and the residue was then redissolved in toluene and evaporated to dryness. Toluene (30ml) and ethanol (120ml) were added dropwise over a period of 30min.. The mixture was stirred at room temperature overnight. The solvent was then dried (MgSO_4) and evaporated and the residue was purified by chromatography on silica gel with 5% ethyl acetate in iso-hexane as eluant, to give the title compound as a yellow solid (8 g, 78%).

20 ^1H NMR (CDCl₃) δ H: 1.44 (3H, t, $J=7.1$ Hz), 4.45 (2H, q, $J=7.1$ Hz), 8.67 (1H, s), 8.72 (1H, s), 8.80 (1H, s).

Ethyl 3-amino-5-iodobenzoate


25 Zinc powder (13.6g, 0.21mol) was added over 20 min. to a solution of ethyl 3-iodo-5-nitrobenzoate (7.4g, 0.023mol) in acetic acid (200 ml) at 0°C. The reaction mixture was stirred for 1hour then filtered and evaporated. The residue was dissoived in diethyl ether and 1M NaOH solution. The layers were separated and the organic layer was then extracted with 1M HCl solution (3x20 ml). The combined acidic layers were basified with 1M NaOH solution and extracted with diethyl ether (2x30 ml). The combined organic layers

were dried ($MgSO_4$) and concentrated. Purification was carried out on silica gel with 15% ethyl acetate in iso-hexane as eluant to give the title compound.

1H NMR ($CDCl_3$) δ H: 1.36 (3H, t, $J=7.1$ Hz), 3.94 (2H, bs), 4.33 (2H, q, $J=7.1$ Hz), 7.17 (1H, s), 7.28 (1H, s), 7.69 (1H, s).

5

Ethyl 3-(acetylamino)-5-iodobenzoate




Acetic anhydride (0.92 ml, 0.0097 mol) was added to a solution of ethyl 3-amino-5-iodobenzoate (2.57g, 0.0089 mol) and triethylamine (1.35ml, 0.0097mol) in CH_2Cl_2 and

10 stirred at room temperature for 4h. More acetic anhydride (0.92ml) and triethylamine (1.35ml) were added and the mixture stirred for other 2h. The reaction mixture was diluted with more CH_2Cl_2 and washed sequentially with 1M HCl and 1M NaOH solution, dried and evaporated. The residue was triturated with dichloromethane and iso-hexane to yeld the title compound (1.2g, 41%) as a white solid.

15 1H NMR ($CDCl_3$) δ H: 1.38 (3H, t, $J=7.1$ Hz), 2.19 (3H, s), 4.36 (2H, q, $J=7.1$ Hz), 7.91 (1H, s), 8.1 (1H, s), 8.34 (1H, s).

Ethyl 3-(acetylamino)-5-(3-bromo-4-pyridinyl)benzoate



20

1.6M BuLi in hexanes (3ml, 0.0048mol) was added over 10min. to a solution of diisopropylamine (0.68ml, 0.0048mol) in THF(10ml) at $-78^{\circ}C$ under nitrogen. The solution was stirred for 10min. then allowed to warm to room temperature and added to a solution of 3-bromopyridine (0.39ml, 0.004mol) in THF (6ml) at $-95^{\circ}C$ over 15 min. The reaction


25 mixture was stirred for 25 min before a solution of 0.5M $ZnCl_2$ (8.1ml) in THF was slowly added. The solution was then warmed to room temperature and ethyl 3-(acetylamino)-5-iodobenzoate (0.5g, 0.0015mol) and $Pd(PPh_3)_4$ in THF (10ml) were added. The mixture was refluxed for 3 hours, cooled and evaporated. The residue was dissolved in diethyl ether and washed with 1M NaOH solution. The organic layer was dried ($MgSO_4$), filtered and concentrated to give an orange solid that was crystallized from iso-hexane and dichloromethane to yeld the title compound as a white solid.

30 LC/MS: $R_t=2.95$ $[MH^+]=365, 366$ $[MH^-]=362, 364$

General procedure B

35


3-[2-(BenzylOxy)-5-(trifluoromethyl)-phenyl]-pyridin-4-yl]-5-(acetylamino)-benzoic acid ethyl ester



5 2-(BenzylOxy)-5-(trifluoromethyl)-benzeneboronic acid (47mg, 0.158mmol), Pd(PPh₃)₄ (19mg, 0.015mmol), potassium carbonate (177mg, 1.27mmol) and ethyl 3-(acetylamino)-5-(3-bromo-pyridin-4-yl)benzoate (70mg, 0.19mmol) in toluene-ethanol (1:1 6ml) were stirred at 90°C, under nitrogen overnight. Upon cooling, the reaction mixture was poured into water and extracted with ethyl acetate (3x10ml). The combined organic layers were dried (MgSO₄), and concentrated. The residue was purified on an SPE column using iso-hexane containing a gradient of ethyl acetate (50-90%) to give the title compound as a white solid.

10 LC/MS: Rt=3.52 [MH⁺]=535,536 [MH⁻]=533,534


15 3-[2-(4-Fluoro-benzylOxy)-5-(trifluoromethyl)-phenyl]-pyridin-4-yl]-5-(acetylamino)-benzoic acid ethyl ester



20 Prepared according to general procedure B but using 2-(4-fluorobenzylOxy)-5-(trifluoromethyl)-benzeneboronic acid instead of 2-(benzylOxy)-5-(trifluoromethyl)-benzeneboronic acid.

LC/MS: Rt=3.57 [MH⁺]=571,572 [MH⁻]=569,570

25 3-[2-(2,4-Difluoro-benzylOxy)-5-(trifluoromethyl)-phenyl]-pyridin-4-yl]-5-(acetylamino)-benzoic acid ethyl ester




Prepared according to general procedure L but using 2-(2,4-Difluorobenzyl)oxy)-5-(trifluoromethyl)-benzeneboronic acid instead of 2-(benzyloxy)-5-(trifluoromethyl)-benzeneboronic acid.

LC/MS: Rt=3.55 [MH⁺]=553,554 [MH⁻]=551,552

5

3-[3-[2-(Benzyl)oxy]-phenyl]-pyridin-4-yl]-5-(acetylamino)-benzoic acid ethyl ester




Prepared according to general procedure B but using 2-(benzyloxy)phenylboronic acid

10 instead of 2-(benzyloxy)-5-(trifluoromethyl)benzeneboronic acid.

LC/MS: Rt=3.28 [MH⁺]=467,468 [MH⁻]=465,466

General procedure C

15 Example 13: 3-[3-[2-(Benzyl)oxy]-5-(trifluoromethyl)-phenyl]-pyridin-4-yl]-5-(acetylamino)-benzoic acid




3-[3-[2-(Benzyl)oxy]-5-(trifluoromethyl)-phenyl]-pyridin-4-yl]-5-(acetylamino)-benzoic acid ethyl ester (56 mg, 0.105mmol) and NaOH (16mg, 0.42) were dissolved in ethanol (3ml)

20 and H₂O (1ml). The mixture was heated at 60°C for 3 hours. The solution was then diluted with water and acidified with acetic acid. The mixture was extracted with ethyl acetate and the organic solution was dried over magnesium sulphate, filtered and evaporated to give the title compound.

LC/MS: Rt=3.21 [MH⁺]=507,508 [MH⁻]=505,506

25


Example 14: 3-[3-[2-(4-Fluoro-benzyl)oxy]-5-(trifluoromethyl)-phenyl]-pyridin-4-yl]-5-(acetylamino)-benzoic acid



Prepared according to general procedure C except 3-[3-[2-(benzyloxy)-5-(trifluoromethyl)-phenyl]-pyridin-4-yl]-5-(acetylamino)-benzoic acid ethyl ester was replaced with 3-[3-[2-(4-fluoro-benzyloxy)-5-(trifluoromethyl)-phenyl]-pyridin-4-yl]-5-(acetylamino)-benzoic acid ethyl ester.

5 LC/MS: Rt=3.25 [MH⁺]=525,526 [MH⁻]=523,524.


Example 15: 3-[3-[2-(2,4-Difluoro-benzyloxy)-5-(trifluoromethyl)-phenyl]-pyridin-4-yl]-5-(acetylamino)-benzoic acid



10 Prepared according to general procedure C except 3-[3-[2-(benzyloxy)-5-(trifluoromethyl)-phenyl]-pyridin-4-yl]-5-(acetylamino)-benzoic acid ethyl ester was replaced with 3-[3-[2-(2,4-difluoro-benzyloxy)-5-(trifluoromethyl)-phenyl]-pyridin-4-yl]-5-(acetylamino)-benzoic acid ethyl ester.

15 LC/MS: Rt=3.27 [MH⁺]=543,544 [MH⁻]=541,542.

Example 16: 3-[3-[2-(BenzylOxy)-phenyl]-pyridin-4-yl]-5-(acetylamino)-benzoic acid



20 Prepared according to general procedure C except 3-[3-[2-(benzyloxy)-5-(trifluoromethyl)-phenyl]-pyridin-4-yl]-5-(acetylamino)-benzoic acid ethyl ester was replaced with 3-[3-[2-(BenzylOxy)-phenyl]-pyridin-4-yl]-5-(acetylamino)-benzoic acid ethyl ester..
LC/MS: Rt=2.88 [MH⁺]=439,440 [MH⁻]=437,438.

25 It is to be understood that the present invention covers all combinations of particular and preferred subgroups described herein above.

ASSAYS FOR DETERMINING BIOLOGICAL ACTIVITY

30 The compounds of formula (I) can be tested using the following assays to demonstrate their prostaglandin antagonist or agonist activity *in vitro* and *in vivo* and their selectivity. The prostaglandin receptors investigated are DP, EP₁, EP₂, EP₃, EP₄, FP, IP and TP.

The ability of compounds to antagonise EP₁ & EP₃ receptors may be demonstrated using a functional calcium mobilisation assay. Briefly, the antagonist properties of compounds are assessed by their ability to inhibit the mobilisation of intracellular calcium ([Ca²⁺]_i) in response to activation of EP₁ or EP₃ receptors by the natural agonist hormone

5 prostaglandin E₂ (PGE₂). Increasing concentrations of antagonist reduce the amount of calcium that a given concentration of PGE₂ can mobilise. The net effect is to displace the PGE₂ concentration-effect curve to higher concentrations of PGE₂. The amount of calcium produced is assessed using a calcium-sensitive fluorescent dye such as Fluo-3, AM and a suitable instrument such as a Fluorimetric Imaging Plate Reader (FLIPR). Increasing

10 amounts of [Ca²⁺]_i produced by receptor activation increase the amount of fluorescence produced by the dye and give rise to an increasing signal. The signal may be detected using the FLIPR instrument and the data generated may be analysed with suitable curve-fitting software.

15 The human EP₁ or EP₃ calcium mobilisation assay (hereafter referred to as 'the calcium assay') utilises Chinese hamster ovary-K1 (CHO-K1) cells into which a stable vector containing either EP₁ or EP₃ cDNA has previously been transfected. Cells are cultured in suitable flasks containing culture medium such as DMEM:F-12 supplemented with 10% v/v foetal calf serum, 2mM L-glutamine, 0.25mg/ml geneticin and 10µg/ml puromycin.

20 For assay, cells are harvested using a proprietary reagent that dislodges cells such as Versene. Cells are re-suspended in a suitable quantity of fresh culture media for introduction into a 384-well plate. Following incubation for 24 hours at 37°C the culture media is replaced with a medium containing fluo-3 and the detergent pluronic acid, and a further incubation takes place. Concentrations of compounds are then added to the plate in order to construct concentration-effect curves. This may be performed on the FLIPR in order to assess the agonist properties of the compounds. Concentrations of PGE₂ are then added to the plate in order to assess the antagonist properties of the compounds.

25

30 The data so generated may be analysed by means of a computerised curve-fitting routine. The concentration of compound that elicits a half-maximal inhibition of the calcium mobilisation induced by PGE₂ (pIC₅₀) may then be estimated.

Binding Assay for the Human Prostanoid EP₁ Receptor

35 Competition assay using [³H]-PGE₂.

Compound potencies are determined using a radioligand binding assay. In this assay compound potencies are determined from their ability to compete with tritiated

40 prostaglandin E₂ ([³H]-PGE₂) for binding to the human EP₁ receptor.

This assay utilises Chinese hamster ovary-K1 (CHO-K1) cells into which a stable vector containing the EP₁ cDNA has previously been transfected. Cells are cultured in suitable

flasks containing culture medium such as DMEM:F-12 supplemented with 10% v/v foetal calf serum, 2mM L-glutamine, 0.25mg/ml geneticin, 10µg/ml puromycin and 10µM indomethacin.

- 5 Cells are detached from the culture flasks by incubation in calcium and magnesium free phosphate buffered saline containing 1 mM disodium ethylenediaminetetraacetic acid (Na₂EDTA) and 10µM indomethacin for 5 min. The cells are isolated by centrifugation at 250xg for 5mins and suspended in an ice cold buffer such as 50 mM Tris, 1mM Na₂EDTA, 140mM NaCl, 10µM indomethacin (pH 7.4). The cells are homogenised using a Polytron tissue disrupter (2x10s burst at full setting), centrifuged at 48,000xg for 20mins and the pellet containing the membrane fraction is washed three times by suspension and centrifugation at 48,000xg for 20mins. The final membrane pellet is suspended in an assay buffer such as 10mM 2-[N-morpholino]ethanesulphonic acid, 1mM Na₂EDTA, 10mM MgCl₂ (pH 6). Aliquots are frozen at -80°C until required.

- 10
- 15 For the binding assay the cell membranes, competing compounds and [³H]-PGE₂ (3nM final assay concentration) are incubated in a final volume of 100µl for 30 min at 30°C. All reagents are prepared in assay buffer. Reactions are terminated by rapid vacuum filtration over GF/B filters using a Brandell cell harvester. The filters are washed with ice cold assay buffer, dried and the radioactivity retained on the filters is measured by liquid scintillation counting in Packard TopCount scintillation counter.

- 20
- 25 The data are analysed using non linear curve fitting techniques (GraphPad Prism 3) to determine the concentration of compound producing 50% inhibition of specific binding (IC₅₀).

By application of these techniques, compounds of the examples had an antagonist pIC₅₀ value of >6.0 at EP₁ receptors and pIC50 value of < 6.0 at EP₃ receptors.


- 30 No toxicological effects are indicated/expected when a compound (of the invention) is administered in the above mentioned dosage range.

The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of product, composition, process, or use claims and may include, by way of example and without limitation the following claims:

- 35

CLAIMS

1. A compound of formula (I):



(I)

5

wherein:

A represents an optionally substituted aryl, or an optionally substituted 5- or 6- membered heterocyclyl ring, or an optionally substituted bicyclic heterocyclyl group;

B represents a phenyl or pyridyl ring;

10 D represents an optionally substituted 5- or 6-membered heterocyclyl ring containing one or two heteroatoms selected from N, S and O;

Z represents O, S, SO, or SO₂;

R¹ represents CO₂H, CN, CONR⁵R⁶, CH₂CO₂H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted SO₂alkyl, SO₂NR⁵R⁶, NR⁵CONR⁵R⁶, COalkyl,

15 2H-tetrazol-5-yl-methyl, optionally substituted bicyclic heterocycle or optionally substituted heterocyclyl;

R^{2a} and R^{2b} independently represents hydrogen, halo, optionally substituted alkyl, optionally substituted alkoxy, CN, SO₂alkyl, SR⁵, NO₂, optionally substituted aryl, CONR⁵R⁶ or optionally substituted heteroaryl;

20 R^x represents optionally substituted alkyl wherein 1 or 2 of the non-terminal carbon atoms are optionally replaced by a group independently selected from NR⁴, O and SO_n, wherein n is 0, 1 or 2: or R^x represents optionally substituted alkenyl, optionally substituted CQ^aQ^b-heterocyclyl, optionally substituted CQ^aQ^b-bicyclic heterocyclyl or optionally substituted CQ^aQ^b-aryl;

25 R⁴ represents hydrogen or an optionally substituted alkyl;

R⁵ represents hydrogen or an optionally substituted alkyl;

R⁶ represents hydrogen or optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted SO₂aryl, optionally substituted SO₂alkyl, optionally substituted SO₂heteroaryl, CN, optionally substituted CQ^aQ^baryl, optionally substituted

30 CQ^aQ^bheteroaryl or COR⁷;



R⁷ represents hydrogen, optionally substituted alkyl, optionally substituted heteroaryl or optionally substituted aryl;

Q^a and Q^b are independently selected from hydrogen and CH₃;


wherein when A is a 6-membered ring the R¹ substituent and the D ring are attached to

35 carbon atoms 1,2-, 1,3- or 1,4- relative to each other, and when A is a five-membered ring

or bicyclic heterocycll group the R¹ substituent and the D ring are attached to substitutable carbon atoms 1,2- or 1,3- relative to each other,
or derivatives thereof;
provided that D is not imidazolyl, thiienyl,



or



wherein A and B are as hereinbefore defined.

THIS PAGE BLANK (USPTO)

PCT/EP2004/011366



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.